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I. Introduction: Antagonists and Antibiotics 
The recent widely publicize9 and epoch-making devel-
opments in the field of bacterial chemotherapy have been 
largely b~sed on three important discoveries made during 
-
the past two decades. The first of these WAS the discovery 
of penicillin by Fleming (17) in 1929; the second was.the 
early work on synthetic chemotherapeutic agents by Domagk 
(8) in 1935 which provided t~e ground work for the subse-
quent synthesis of the sulfonamides; and the third was the 
isolation of a therapeutically effective antibiotic agent 
from a soil bacillus by Dubos (9) in 1939. 
As a result of the dramatic success attending attempts 
to apply the above discoveries to the treatment of human 
infectious diseases, unprecedented interest and research 
efforts are now_ being directed at the problem of producing 
new and even more effective chemotherapeu~ic agents. ·That 
this renewed activity on the part of the microbiologists, 
the chemist, the physiologist and the clinical investigator 
is warranted in this connection was well expressed by S~r 
Alexa~der Fleming in the Lister Memorial Lecture (1944}, 
when he stated: 
"Penicillin may be making some small revolution 
in surgery, and I am glad to have had some part in 
it. It is, however, not the end. There is still plenty 
of scope for the.chemist to synthesize penicillin, and 
then tinkerw.ith the molecule so that the present. imper-
fections of penicillin can be remedied. Then there are 
) 
) 
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thousands ·of micro-organisms other than Penicillium· 
notatum which can manufacture in their growth compli-
cated substances, and some of these may be better than 
penicillin, or they may· have a constitution which will 
give a clue to fresh chemical linkages which are destruc-
tive to bacteria." 
While penicillin is to date the most effective anti-
biotic agent known, it should not be assumed that it was the 
first antibiotic to be discovered, for this is distinctly not 
the case. It was in the earliest years of the science of bac-
teriology that microbial antagonismswere first observed, and 
there was little delay in attempting to employ these, crudely 
and ineffectively to be sure, in the treatment of infections. 
Pasteur and Joubert (47) in 1877 noted that certain con-
taminati~g organisms exerted an antagonistic effect on the 
growth of Bacillus anthraci~; and that simultaneous inoculation 
of susceptible animals with certain other bacteria along with 
the anthr~~J bacillus repressed the development of anthrax. 
Since the time of Pasteur, numerous investigations have 
been carried out and a vast amount of information has been 
accumulated with respect to microbial antago~isms. In fact, 
antibiotic substances have been detected, and i~ some cases 
isolated, from almost all types of living organisms. 
Bacteria were investigated early and many bacterial 
antagonisms were discovered in vitro and in vivo. For 
" instance, it was noted that accompanying flora could either 
inhibit or favor the growth of an organism; that the growth 
of an antagonistic organism was favored by the presence of 
organisms which it inhibited; that different strains varied 
0 
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in their ability to inhibit or be inhibited; that environ-
mental conditions affected the production and persisteEce 
of activity of antibiotic substances; that filtrates from 
cultures of antagonistic organisms inhibited only certain 
susceptible organisms; that certain organisms could dest~oy 
bacterial toxins; that some filtrates were active against 
fungi; that the antagonistic action varietl from inhibition 
of growth to actual bacteriolysis of susceptibae organisms; 
and that antibiotic agents varied widely in their toxicity 
to animals and in their chemical constitution. c;he most 
prominent antibiotic agents to be derived from bacteria 
thus ~ar are-listed on Tagle~ It is worth noting here 
that pyocyanase was the first ~ntibiotic agent to be used 
for the treatment of infection in the year 1899 ( 12). 
Various fungi have been demonstrated to possess anffiag-
onistic activity against bacteria, other~fungi, viruses, 
insects and other animal forms. Active antibiotic substances 
have been isolated from many species of fungi, and their 
therapeutic application has ranged from the treatment of 
P.~~n~ disease to that of animal and human diseases. ~he 
more important antibiotics of fungal origin are listed in 
' v~ ~ 
Table II; of these only penicillin has achieved widespread~ 
clinical u~ 
Although there has been but little investigation of 
the antagonistic properties of viruses, it is known that 
they may be destroyed by other micro-organisms, and that 
some viruses can antagonize certain other viruses. No 
therapeutic application of this knowledge has yet been 
) 
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reported although it has been demonstrated that a murine 
mutant strain of poliomyelitis virus counteracted large 
paralytic doses of the parent strain, presumably by means 
of a chemical substance uroduced by the former (69). 
Complex antagonistic and associative relationships 
have been discovered between bacteria and fungi on the 
\ 
one hand, and animal forms such as protozoa, insects, 
insect larvae, worms and higher animals on the other hand. 
Antagonistic relations have long been known to exist be-
tween various animal forms, even including the so-called 
uhigher animals". ~ 'examples of tbe production of anti-
a-re. bacterial substances in higher animals ~ afforded b~ th~ 
presence of lysozyme in mammalian tissues and-secretions, 
anA;\he inhibin contained in fresh burna~ urine. The im-
mune bodies produced by higher animal forms are analogous 
in some respects to some antibiotic substances of microbial 
origin ( 69). 
Whil~ antagonistic activity of certain actinomycetes 
was described as early as 1890, a systematic study of the 
group with the object of isolating therapeutically useful 1 
i 
antibiotic agents was not undertaken until_ 1939 (85,77~8~ 
70).[irable III lists the more important antibiotic agents 
of actinomycetes origin; the last agent listed, streptomy-
cin, is the most promising of the group, and forms the sub-
ject of tbis paper. 
) 
J 
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II. Events Leading up to the Isolation of Streptomycin 
Although certain of the sulfonamides have been demon-
strated to have some therapeutic effect on various gram-
negative infections, their relative inefficacy and rather 
high incidence of toxic reactions make the development 
of superior agents likely as well as desirable. Tyrothri-
cin, a rather toxic substance isolated by Dubos in 1939 
from a soil bacterium, Bacillus brevis, has also been found 
' 
to have little or no effect on gram negative organisms (9). 
Even before the efficacy and exact chemotherapeutic poten-
tialities of peNicillin were fully explored it was evident 
that this agent was not capable of controlling infections 
due to most gram-negative organisms. Thus it was that in 
. 
1S39 Waksman and his co-workers at the New Jersey Agricul-
tural Experiment Station of Rutgers University undertook 
the investigation of various groups of micro-organism~ · 
with the aim of isolating substances which could be util-
ized for the treatment of gram-negative infections {83). 
Several substances of m0ld origin--clavacin, fumigacin, 
and chaetomin, and of actinomycetes origin--actinomycin 
and micromonosporin, were i~olated, but testing soon re-
vealed that tnese were unsuited for chemotheraoeutic use 
by reason of excessive toxicity or limited potency or 
both. 
Preliminary studies on t~e group of actinomycetes 
revealed that many of these possessed striking anti-
bacterial properties {85,77,87,70). Thousands of cultures 
isolated from normal and enriched so1ls, composts, manures 
) 
) 
-6-
and other natural sources, and from type collections were 
exhaustively tested and analyzed with the result that sev-
eral promising organisms were selected for further stu~y. 
From one of these, Actinomyces lavendulae, a substance 
designated as streptothricin was isolated (85,84,71); this 
was found to be active in vitro against many gram-positive 
and gram-negative organisms(84,71,20,58,39), against path-
ogenic fungi (59) and.against mycobacteria(B9). It was 
demonstrated also to be effective in !!Y£ against experi-
mental infections by gram-negative organisms (42,55,58,57). 
HowevPr, more recent studies have revealed that certain 
gram-negative and gram-positive organisms are naturally 
resistant to streptothricin in fairly high concentrations· 
(61,81). In addition,pharmacologic studies indicate that 
streptothricin has a delayed toxic effect in experimental 
animals, with production of necrosis and even gangrene 
df the small intestine, arteritis, myocarditis, renal tub-
-
ular lesions, and occasionally hepatic and central nervous 
system lesions following intravenous aaministration; with 
subcutaneous administration only renal lesions occur. 
These untoward effects o~ systemic administration strong~~ 
contraindicate the use of streptothricin in human beings, 
and Herrell (31) has suggested that the use of the sub-
stance-be restricted to local treatment of infected wounds 
and burns and of infected body cavities. Oral administra-
tion for intestinal infectlons as suggested by Robinson 
et:al (57) would seem to be a hazardous procedure, espe-
cially in view of the fact that equally effective and less 
) 
) 
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~oxic agents are available for this purpose. 
When it became evident that streptothricin did not 
fulfill the requirements of in vivo potency and pharmaco-
logic freedom from toxicity, the search continued. In 
danuary, 1944, ¥~ksman and his~udents, Schatz and Bugie 
(61), isolated an actinomycetes which was similar in mor-
phological and cultural characteristics to an organism iso-
lated 28 years previously by Waksman, and designated as 
Actinomyces griseus (72}. The antibiotic substance produced 
by this organism was found to be similar to streptothricin 
with respect to many of it~ physical, chemical, and antibac-
terial properties, and in the method of its isolation from 
cultures; it differed with respect to the cultural require-
ments for its optimal production, its antibacterial spectrum 
and ~ts quantitative activity against certain organisms. 
It was found early to possess many desirable antibiotic and 
pharmacological properties and was designated streptomycin, 
in accordance with the generic name Streptomyces pro~osed 
by Waksman and Henrici (76) ~or the sporulating and aerial-
mycelium producing group of actinomycetes. Two active 
strains of s. griseus were obtained, one (No. l8-16) from 
heavily manured soil, and the other (No. D-1} somewhat less 
active, from a smear plat~ of a chicken's throat. The 
organism is not believed to be a normal inhabitant of the 
animal system. 
~e IV summarizes the comparative chemical and 
biological properties of streptothricin and streptomycin. 
). 
) 
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III. Production 
The production of antibiotic substances from micro-
organisms involves several steps. The first of these 
is the stimulation of growth of the micro-organism~ in 
question by introducing into the soil specific bacteria 
against which it is antagonistic; this step may ~e omit-
ted if the soil already contains the specific antagonistic 
organisms. The soil is then plated upon agar media con-
taining washed living cells of bacteria as the so1~ source ' 
of carbon and nitrogen for the growth of organisms capable 
of destroying the bacteria. After determin~ng the specific 
antibacterial spectra (e.g. by the agar streak method), 
favorable cultural conditions are selected for the produc-
tion of the. specific antibiotic substance, which is then 
concentrated and purified. As a final preliminary step 
to clinical application, the antibiotic agent is studied 
for in vivo activity and pharmacologic properties. This 
procedure was employed for the isolation of strep~omycin 
as well as streptothricin. 
In contrast to streptothricin, which is produced on 
a variety of simple or complex media, such as glucose-
tryptone, starch-tryptone or simple synthetic media, strap-
tomycin production requires the presence of complex growth-
promoting substances such as those provided by meat extract 
or corn steep liquor. ~ 
Growth of s. griseus was demonstrated at the outset 
(61) to be more rapid in shaken submerged cultures (68,88) 
-----than in stationary cultures. Both methods, however, yield 
\ 
) 
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considerable streptomycin production, maximum activity be-
ing reached in two or three days ·with the submerged technic 
and in 9 to 12 days with the stationary method. Th~ organ-
ism grows intne form of very fine colonies which imp~1t 
some degree of turbidity and light brown color to the medium. 
Optimal antibiotic activity is achieved by adding 2.5 to 5.5 
grams of meat extract per liter of medium; corn steep liquor 
may replace the meat extract, but this complicates the sub-
sequent processes of purification. The nitrogen require-
ments of the organism may be supplied by many common nitro-
gen sources--peptone, casein, tryptone, amino acids or 
even sodium nitrate. While glucose favors the production 
of streptomycin and is the best carbon source for use in 
stationary cultures,~ it may s,afely be replaced by starch , 
and glycerol, and is actually inferior to dextrin and lac-
tose for use in submerged cultures. The carbohydrate is 
presumed to function either·. as a source of energy or of acid 
for the n~tralization of the alkalinity produced by the gr0wth 
of the organism. This latter factor is important, since the 
reaction of the medium usually reaches pH 7.7 to 8.6 or more, 
and excessive alkalinity destroys the active substance; 
attempts to limit the rise in pH by adding buffers have not 
been successful (75). 
The basic medium adopted by Waksman and co-workers is: 
Glucose 
Peptone 
Meat Extract 
NaCl 
Tap Water 
Final pH 
lO Gm. 
5 Gm. 
5 Gm. 
5 Gm. 
1000 Ml. 
6.5-7.0 
) 
) 
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Early studies (75) showed that, contrary to what might 
be expected, there is no definite correlation between strep-
tomycin production and either growth of s. griseus, glucose 
consumption or ammonia production. 
More recent investigations (71,63,81) have demonstrated 
. . 
that the strains of s. griseus and A. lavendulae which pro-
duce streptomycin and streptothricin can undergo variation 
to f0rm inactive strains which have lost their ability to 
produce these antibiotic substances. The variants of 
S. griseus differ from the mother culture in certain re-
spects as summarized in Table V; the characteristics of 
the variants are those of the genus Nocardia and suggest 
that naturally' :;occurring members o-r this genus may be de-
generate forms or accidental variants of the Streptom~ces. 
From a practical point of view, it should be emphasized 
that the aetive strains of s. griseus seem to be fairly 
sta~le in antibiotic potency provided the media and cultur-
al conditions are kept constant. Thus the possibility of 
formation of inactive variants does not constitute a ser-
ious threat to streptomycin production, since industrial 
conditions are widely different from those necessary for 
obtaining inactive variants. Never the less inactive lots 
- -
may occasionally result from the use of vegetative growth 
for inoculation purposes. 
Although crude cultures containing streptomycin 
gradually lose activity on standing--presumably due to the 
adverse affect of an enzyme in the culture--streptomycin 
r-. ·~--
is resistant to contaminating organisms as well as to 
-11-
S. gri~eus itself. Concentrated preparations are stable 
for many months, particularly when refrigerated. Strep-
tomycin loses considerable activity, however, on expo-
sure to acids or to glucose, but resists temperatures as 
high as 100 degrees centigrade with only slight loss in 
activity. 
-12-
IV. ISOLATION; PHYSICAL, CHEMICAL AND BIOLOGICAL PROPERTIES 
~ The isolation and concentration of strep~omycin from 
) 
) 
3 
culture media make use of the methods developed for strepto-
thricin (84, 71, 40, 82). Several distinct steps are· involved, 
as follows: 
1. Termination of incubation when maximUm antibiotic 
activity has been reached. 
2. Separation of broth from the mass of growth of the 
organism by centrifugation or filtration, using a filter 
which does not absorb streptomycin. 
3. Adjustment of cell-free alkaline filtrate to neut~ality. 
4. Adsorption of streptomycin on active charcoal 
(Norite A) which is then filtered or centrifuged off. 
5. Washing of charcoal adsorbate with alcohol to 
remove certain impurities, and'then with dilute acid-
alcohol to dissolve the streptomycin. 
6. Neutralization of the acid-alcohol washings which 
have been separated from the charcoal, and filtration 
to remove precipitated impurities. 
7. Concentration ~f the streptomycin solution by removal 
of the alcohol with ten volumes of ether, leaving 
a yellow, brown or red aqueous streptomycin concentrate. 
8. Preparation of a solid streptomycin concentrate 
by precipitation with acetone or dessication in 
vacuo. 
) 
) 
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Using crude concentrates obtained by the above 
procedures, the bacteriostatic spectrum of streptomycin 
was determined, its pharmacologic properties fairly 
well established, and its physico-chemical nature 
revealed as a water-soluble, fat-solvent insoluble, 
thermostable nitrogenous organic base. However, more 
refined preparations were sought as a means of eliminating 
toxic reactions due to impuritie~ and of better standard-
ization of dosage with preparations of constant high 
potency. ~ / 
The first crystalline salt of streptomycin to be 
obtained (22) was the reineckate, prepared by Fried and 
Wintersteiner by the following method: 
1'3Adsorption of the active principleffrom cultures 
onto _charcoal. 
2. Elution with dilute mineral acid. 
3. Pre6ipitation by phosphotungstic acid. 
4. Conversion of the bases liberated from the 
phosphotungstate into a crude picrate and fraction-
ation of the latter by chromatographic methods. 
5. Isolation of the water-soluble amorphous products 
of high activity after removal of the picric acid 
from one or more of the above fractions. 
6. Formation of crystalline precipitates by addition of 
Reinecke Salt, NH4 ~r{SCI~)4(N'H3.)2J to an aqueous solution 
of active amorphous products. 
7. Fractional crystallization to produce pure strepto-
mycin reineckate with a potency of 370-410 units per mg. 
) 
) 
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It was found that the crystalline reine?kate crystallized 
from water in thin plates which dacomposed at 162-164 
degrees c. (Corr.). Although the empir~cal formula could 
not be determined due to inconsistencies in some of the 
analytical figures~ the formula (C14H2607N9S4Cr)n or 
(C14H2602N9S4Cr)n, corresponding to tClblil907-8N3)n 
for the basic component were proposed as being in 
reasonable accord with the analytic data, with the 
objective of providing a basis for calculating the potency 
of free streptomycin. Since two preparations of strepto-
mycin reineckate were found to have potencies of 370 
and 410 units per mg,- it was concluded that the pure base 
probably has a potency of approximately 800-910 units per 
mg. Streptomycin sulfate, obtained by decomposition of 
the reineckate with silver sulfate (Ag2so4 ), had an activity 
of 850 units per mg. 
Another c~ystalline salt of streptomycin, the helian-
thate, has recently been obtained (40), and it seems to be 
superior to the reineckate for preparative work. This com-
pound was obtained by treating highly purified concentrates-
of streptomycin1 such as the acidic eluate of the charcoal 
adsorbat~with methyl orange {the sodium salt of helian-
thine). This resulted in the crystallization of water-
-insoluble streptomycin helianthate, which was then recryst-
allized from aqueous methanol and the anhydrous form obtained 
by heating at 100 degrees c. in vacuo. Assay using the cup 
method with B. subtilis as test organism indicated that the 
) 
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compound had an activity of about 350 units per mg. It 
was found to darken at 205 degrees C. and melt with 
decomposition at 220-226 deg c. 
The hydrocholoride can be produced by heating the 
helianthate with a me~hanol-hydrochloric acid mixture, 
removing the liberated helianthine, and adding ether to 
precipitate the amorphous white hydrochloride from the 
filtrate. After drying over phosphor¢us pentoxide at 
25 deg. in vacuo, this salt has a specific rotation of 
(~) - -8~0 (C,0.5% in water} and an activity of about 
n-
800 units er mg. Microanalytical data were insufficient 
to assign definite empirical formula, but indicated that 
there wa§ , o sulfur or phosphorus in the molecule. The 
I 
ultraviolet adsorption spectra of streptomycin in phosphate 
f 
buffer at pH 7, in borate buffer at pH 9 and in glycine 
buffer
0
at ~H 2 indicated only end absorption below about 
2,300 A. /Other streptomycin salts prepared from the 
heliantha~e showed activity ranging from about 300 to 
520 units ~er mg. 
Addi~iohal chemical studies (48) resulted in the 
} 
prep~ratidn of a crystalline double salt of streptomycin 
trihydrocJloride and calcium chloride from the helianthate, 
! 
1 
by adding !a methanol solution of calcium chloride acidified 
I 
with hydr~chloric~ acid to a methanol suspension of 
streptomy~in helianthateA After removal of the insoluble 
calcium helianthate by filtration and concentration of the 
l 
filtrate in vacuo, colorless o~ystals of the double salt 
were obta~ned. After drying in vacuo at 100 deg c., it 
I 
I 
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was found that the compound had an activity of about 
750 units p~r mg. and («~5 = -76° (0,1% in water). 
Decompositi~n occurred at between 200 and 230 deg o. 
' 
on the micr~block. This compound is considered to be supeP-
1 
ior to the ~orpheus h7drochloride in certain respects, 
since the b~ological, chemical and physical properties of 
the crystal~ine double salt are more constant. Analytical 
data indicale that the formula of streptomycin is 021H37-3~012' 
I 
rather than! (01oH1gN307-8)n as proposed by Fried and Winter-
steiner. A} cryoscopic determ~nation of the molecular weight 
! 
of streptomycin trihydrochloride in water gave approximate~ 
) 
800 for the)free base, and corrections for experimental 
l 
errors seem~d to account for the deviation from the 
calculated ta1ue of 580. 
The moft recent studies indicate that streptomycin has 
t&tgeneral structure of a hydroxylated base, designated 
as streptid~ne, attached by means of a glycosidic linkage 
! 
to a nitrogen Qontaining disaccharide-like molecule, a 
1 
derivative of a parent compound designated as streptobiosamine. 
The streptopiosamine derivative has been shown to contain a 
' l 
. free or pottntial carbonyl group and a methyl-amino group (48). 
Furthe~ experimental data indicate that the structure 
of streptomfcin may be graphically represented as follows: 
I 
l 
! 
J 
) 
J 
J 
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I 
G=O 
I 
0 
I 
Streptobiosamine 
Portion 
Hydrolysis of streptomycin to form streptidine and 
the streptobiosamine derivative may be represented by the 
equation: 
-18-
Streptomycin preparations are suff'icientl-y stable 
as not to require ~ef'rigeration~ but it is recommended that 
they be kept at a temperature not greater than 25° c. At 
this temperature, the material is stable f'or at least nine 
months provided the moisture content is not in excess of' 
three per cent and the pH is :from 6.0 to 7.5. ~olid prepar-
ations are hydroscopic. Dilute sterile solutions may be 
kept at 37 deg a. :for long periods without any loss of' 
potency, and at lQO degrees a. f'or ten minutes with less trran 
fifty per cent loss. 
Streptomycin~ in contrast to penicillin, pyocyanase 
and certain other antibiotics, is neither destroyed nor 
absorbed by resistant or sensitive organisms (78). It 
has been demonstrated that incubation of aqueous and nutrient 
broth solutions of streptomycin with Aspergillus niger or a 
mixed culture of fungi and bacteria for seven days at 
twent-y-eight degrees a. resulted in no greater loss in 
, 
activity than occurred in sterile controls (82). In 
another study, no significant loss of potency occurred a~ter 
incubation with E. coli for seven days at thirty-seven degrees 
a., but considerable loss was noted after fourteen days (91)• 
-19-
v. Standardization and Assay Methods 
Standardization:For purposes of investigation on a quan-
t~tative basis, it was necessary at the outset to define a 
unit of measurement for streptomycin. Since the substance 
" 
had not yet been isolated in pure crystalline form, and 
since quantitative chemical methods for its measurement 
had not yet (and still have n~) been developed, the original 
unit was of necessity based upon antibacterial action as 
det~rmined by biological assay methods. This unit, design-
ated the nsn or E. coli unit, was arbitrarily defined as 
the amount of the material which, when present in one ml. 
of nutrient broth or other suitable medium, will just inhibit 
the growth of a particular _,strain of !• coli (38,73). 
While this unit served as a convenient quantitative 
standard for early exPerimental studies, it was soon found 
to be too small for.phar.macological and clinical purposes. 
Also, comparison with penicillin (Oxford) unitage led to 
confusion since the latter is based upon ihhibitory action 
in 50 ml. of medium, and thus represents much greater ig 
vitro antibacterial activity, although the unit of penicillin 
weighs 0.6 m~crograms as compared with one microgram for 
the streptomycin unit. It should be boriEin mind also, that 
the activity of the penicillin is determined against the 
relatively sensitive gram-positive organism while that of 
streptomycin is determined against the more resistant gram-
negative bacteria (82). vVhen both antibiotics are assayed 
against s. aureus ~'penicillin is found to be.twelve time~ 
as potent, urlt for unit, as streptomycin for that particular 
8 
0 
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test organism. However~ & aureus is many times more sus-
ceptibl~ to penicillin than thergram-negative E. coli, and 
the gram-positive B. subtiL!is is almost ten times more 
sensitive to st~tomycin than E. coli. Thus any comparison 
o~ the relative activity o~ penicillin and streptomycin 
must take into acc.ount the exact conditions o~ assay and 
the test organism used. 
For the reasons given above, larger units o~ 
streptomycin were proposed (73) as ~ollows: 
1. An 11 L11 unit, equal to 1000 S units and defined as the 
ronount of streptomycin which just inhibits the growth 
o~ a standard strain o~ E. coli in one liter o~ medium. 
2. A "G" unit~ equal to 1 gram o~ crystalline material. 
Since one S unit weighs approximately one microgram, an 
L unit is equal to one milligram and a G unit~ de~ined 
s 
as one gram~ turns out to be equal to one millionAunits 
~he hydrochloride salt has been recommended as the re~erence 
standard, with potency stated in terms of the pure base. 
Throughout this ~aper,· unitage will be expressed in 
terms of the original E. coli or S unit. 
0 
0 
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Assay~ethods in general may be used 
quali~atively for the characterization of antibiotic 
agents (i.e. determinatiorybf antibacterial spectra), 
and quantitatively for determining the amount of 
antibiotic activity in a given specimen (e.g. body fluid, 
or ~e or purified preparations of the substance in 
question) against specific test organisms. 
Many methods are available for the biological assay 
of antibiotic substances. The results of these assays 
vary considerably and depend on man~ factors, among 
which are the strain of test organism used, the exact 
conditions of incubation, the reaction and composition of· 
the medium, and the mechanism and peculiar characteristics 
' ! 
of the antibacterial activity of the agent in questionP9# 69). 
For instance, in the case of streptomycin, the optimal 
pH for its activity is 9.0, and greater acidity markedly 
reduces its antibacterial action. In addition, streptomych 
is appreciably inhibited by glucose and certain salts such 
as phosphates \82). Thus it is evident that assay methods 
must be strictly standardized with respect to materials 
and procedures, and that suitable specific methods be 
devised or adapted to fit each purpose for which assay is 
required. Further, interpretation of assay results should 
take into consideration the above factors as well as addition-
al pertinent data to be presented in the section of this 
paper dealing with the characteristics of antibacterial 
action in vitro. 
D 
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Agar Dilution Streak Method: The agar streak method, 
notwithstanding its shortcomingsp with respect to precision 
and speed, is a valuable method of assaying antibiotic 
substances, particularly useful for screening tests with 
numerous organisms, for isolation procedures, for deter.mi~ 
the antibacterial spectra of antibiotic agents, and for 
approximate quantitative estimations. It has the advantages 
o~ not requiring a sterile sample, ahd allowing the testing 
of unknown materials, even in non-aqueous solutions, 
against several organisms simultaneously. In the case of 
streptomycin, this method has been of invaluable service for 
the preliminary isolation and characterization of the 
Bubstance, and is probably the most convenient method for 
its identification at present. 
The test organisms usually employed in this method are 
E. coli (ATCC 9657), representing the grrun-negative group; 
B. subt~x~s~(ATCC 6653), representing the gram-positive 
bacilli; s. aureus (ATGG 6538), representing the coccus 
group; and B. mycoides (ATGC 6462), included for purposes 
of:"' differentiating certain antibiotics from one another 
(e.g. streptomycin from streptothricin). Occasionally 
certain other organisms are included for specific purposes. 
Suspensions of all of the test organisms are streaked 
on each of several agar plates containing various dilutions 
of the solution to be tested. After suitable (standard) 
incubationary periods, the growth of each organism on each 
plate is compared with the growths on control plates. 
The highest dilu~ion at which growth is completely or almost 
lfl.._e completely inhibited is taken as the end point. ~n 
activity of the solution tested is expressed in ndilution 
-q,ni.ts 11 , calculated by dividing the volume of agar in the 
.. -~­
"" "'-..... ..1 _, 
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plate by the amount or antibiotic substance added to the 
plate showing the end point~ gi~ ng the ooncentration 
active substance in units per ml. or the preparation' 79,51). 
Slide Cell Method: The use or a technique modified 
from Fleming's slide cell method for tho/assay of penicillin 
in body fluids was found by Heilman (25) to be satisfactory 
for the estimation of streptomycin levels in normal serum, 
spinal fluid, and bile. The r.esults of urinary assays, · 
however, were 11 irregular 11 , and specimens or bile required 
dilution with an equal volume of Oo84% NaCl to avoid the 
hemolytic effect or undiluted bile. 
The procedure is in general similar to Fleming's 
modification or the Wright slide cell technic, differing 
chiefly by the substitution of B. megatherium for 
Streptococcus pyogenes as the test organism. Previously 
heated sterile defibrinated human blood is inoculated ~th 
broth. 
a twenty-four hourAculture or the test organism, and 
portions are quantitatively added to each of several test 
tubes containing appropriate dilutions or standard 
streptomycin solutions and or the unknown solutions. 
Portions of the contents of each tube are added to slide 
cells and incubated for 18 hours at 3~0 c. The end 
point is taken as the highest dilution of standard or 
unknown solution which completely prevents hw,molysis. 
From this, the concentration of streptomycin in the 
undiluted Unknown specimen is calculated by multiplying 
the dilution factor by the number of units of the 
standard causing inhibition of hemawsis in the same test. 
0 
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While the slide cell method has the advantages of 
being easier to perform··and requiring fewer materials than 
: ( 
the cup method, it is'inferior to the cup method for ac-
curate determinations of ~mall concentrations of strepto-
mycin and for urinary assays. The slide c~ll method is not 
irrterfered with by the presence of therapeutic levels of 
the sulfonamides, bu~he ~ffect_of penicillin varies with 
its relative concentration as compared with the streptomycin 
concentration. Within certain strict limitations, each 
drug can be assayed in ~he presence of the other. Per-
haps the use of an as yet Undiscovered specific inactivator 
of ~~reptomycin together with penicillinase will facilitate 
the assay of penicillin in the.presence of streptomycin 
and vice versa • 
.............. 
Agar Cup (Cylinder Plate) Method: · Another procedure 
~or penicillin assay, the Oxford cup method, has been mod~ 
ified by Foster and Woodruff (21} for the determination of 
streptothrici~and by Stebbins and Robinson (67)· for the 
determinin§tion of streptomycin. The second modification 
is largely based upon the first, the chief difference being 
the substitut~n of §. aureus ·SM for ~. subtilis as the 
test organism, since normal blood inhibits the latter organ~ 
ism and not the former (11). In addition, the pH of the 
medium has been increased to 7.5 ~.o, and the salt concen-
tration decreased considerably. 
Beveled glass or porcelain cylinders are ~ealed to 
the surface of agar plates containing a lo-5 dilution of 
0 
0 
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a six hour broth culture of the test organism. Suitable 
normal serum dilutions of an aliquot ®f the streptomycin 
solution being administered to the patient and of the 
unknown test solution are placed in the cylinders, incu-
bated for 16wl8 hours at 30° c., ar1d the resulting zones 
of inhibition then measured. A standard curve of reference 
is constructed from the values for the known solution) by 
plotting the diameters in millimeters of the zones of in-
hibition against the concentrations of streptomycin in 
units per ml. The concentration of the unknmwn solution 
is determined by reference to the standard curve with cor-
rections applied for dil~tion. In assaying urine, feces, 
or tissue extracts, distilled water is used as the diluent 
instead pf normal serum. Horse serum may be substituted 
for the patient's serum or normal human serum for diluting 
standard solutions without altering the results obtained,2). 
The cup method using the above procedure has been demonstrated 
to be sufficiently accurate for satisfactory biol®gical assay 
-
of streptemycin, particularly for concentrations between 
one and twenty units per ml. It has the fUrther advant-
~ 
ages of simplicity and convenience, in that sterile pre~ 
. ~ 
parations are not essential and several preparations or " 
. -
duplicates can be run on the same plate. It has the dis-
advantages of requiring a standard preparation for ~efer­
ence, and of being of little or no value for the compar-
ison of different substances, due to differences in water-
solubility and rate of diffusion. The method is limited to 
0 0 
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the assay of water-soluble diffusible substances1 and even 
with these~ difficulty is occasionally encountered in obtain" 
ing regular zones of diffusion (21 691 79)~ 
Paper Disc-Plate Method: The recently described paper 
dise•plate method (41) employs the agar diffusion principle 
for the assay of streptomycin prepared in phosphate buffer 
~olution at pH 7.9 or in culture broth. Agar containing 
~ subtilis spores is poured up~he surface of solidified, 
§terile agar plates, which can be stored safely for several 
0 days at 2-4 c. until needed. The_ streptomycin solutions 
to be assayed are added Dapidly (within five seconds) in 
o.o8 ml. portions to dry filter paper disks on the surface 
of the agar.. The diameters of the zones of inhibition are 
measured aft~r 15 hours incubation at 30° c. or ~6 hours 
at 37° c. The expected standard error of this method is 
said to be 8.5% when eight discs are used for each solution 
tested(41). 
Test Tube Agar Diffusion Method: This method has recent~ 
~Y been proposed by Asheshov and Strelitz (3) as suitable 
for use in small laboratories lacking elaborate facilities 
~ 
and highly trained personnel, and for situations where 
large numbers of assays are carried out and where some de-
gree of precision may be sacrificed in favor of simplicity 
and ease of execution. 
Agar stabs are prepared by allow~ng soft nutrient 
agar inoculated with the test organism to solidify in tubes 
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placed in an upright position. Portions ef suitable 
~ dilutions of standard and unknown antibiotic solutions 
) are placed on top of the agar stab, and the amount of aQtivity 
_ is estimateq by the depth of the zone of inhibi~ion extend-
ing downward from the strface of the stab after overnight 
incubation. As in the cup plate method, the concentration 
ot the unknown solutiou is determined by reference to a 
standard curve constructed from the values obtained with 
known solutions. 
Choice of Assay Method: Perhaps, as suggested by Heilman 
(25) 1 it is advantageous to be able to emplo~~more than.one 
method tor the assay of streptomy~in. However, this is by 
-
no means always practicable, and usually a single method is 
chosen after consideraDion of such factors as the mumber 
of assays to be run, the accuracy desired ana the facilities 
available. At present, it appears ~hat the cup plate 
method of Stebbins and Robinson has been the most widely 
adopted technic for quantitative estimation of streptomycin 
concentrations in body fluids and ti~sue extracts. Possibly 
more precise biological or even chemical assay methods will 
be developed in the future. 
Inactivation of Streptomycin: For purposes of de-
termining the sterility of streptomycin preparations, and 
for detection of admixture of other antibacterial agents 
with streptomycin, it would be advantageous ~o have a 
~ ~pecific inactivator of this an&ibiotic. Thus far, no 
0 
D 
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such substance has been reported. 
However, certain sulfur containing organic compounds 
have been demonstrated to have the ability to inactivate 
. 
streptomycin along with p~nicillin1 pyocyanifte and numeroUI· 
other antibiotic substances~5~~~e most important of these 
-inactivators is the amino acid cysteine, although 2-smino-
ethanol is only slightly less effective and thioglycollic 
acid also has some inactivating effect. Since cysteine 
has no effect on streptothricin, it can be used to ~iffer­
entiate the latter from streptomycin and to determine the 
amounts of each in mixtures. However, since e~steine 
itself has the power of inhibiting certain organisms in-
cluding ~ subtilis (791 52) 1 selection of the proper test 
organism is of importance in obtaining accurate results. 
~able VI illustrates the the effect of cysteine on the \ 
. _j 
activity of streptomycin.· 
\Vhile the inactivation of most antibiotic agents by 
cysteine is irreversible, the activity of streptomycin is 
quantitatively restore4 by the addition of iodine. This 
is accomplmshed by shaking the cysteinewinactivated strep• 
tomycin solution with small amounts of a carbon tetra-
chloride solution of iodine until decolerization no longer 
occurs. 
The mechanism of inactivation of streptomycin by 
cysteine is not known; perhaps it involves a competitive 
effect on bacterial metabolic processes or a reversible 
~ ---~~hemieal reaction between streptomycin and cysteine. 
~ At any rate, the inhibiti?n of streptomycin does not de-
pend on the sulfhydryl group alone (7). 
VI. Pharmacology and Toxicology 
In experimental animals: In gene~al1 streptemycin closely 
resembles penicillin with respect to pharmacol•gic and toxico• 
logic propeDties. Results of animal experiments by ~obin~ 
son ~ ~ (591 56) indicatedthat parenteral administration 
is capable of producing therapeutically effective blood 
levels of streptomycin. Multiple divided d'oses given intra-
ven~usly or subcutaneously ~very six hours for 24 hours 
are ~qually effective as single doses of the same total 
amount of drug in protecting mice against lethal infections 
by streptomycin sensitive organisms. Oral administration 
requires much higher dosage and is far less effective 
therapeutically; however, examination of the feces of mice 
so treated shows that the gastr~-intestinal tract is 
sterilized insofar as lactose-fermenting organisms are con-
cerned, and that the total bacterial content of the feces 
is eonsiderabl~ decreased. 
Following par~nteral administration, streptomycin 
seems to be widely distributed in the body fluids and 
tissues, and MUrphy and Ravdin (45) have recently demQn-
strated that the drug reaches the peritoneal cavity in 
animals with peritonitis as wellaas normal animals. 
About 70% of the drug is excreted in the urine during the 
first .five or six hours after parenteral administration, 
so that frequent intramuscular injection or c6ntinuous 
intravenous infusion is necessary .for maintenance of 
adequate blood levels. 
In m•st cases, streptomycin is well tolerated by mice, 
rats, guinea pigs, and monkeys when given in rather large 
I 
doses and ~ver extended periods of time. However, certain 
impure preparations of the drug produce acute toxic reactions 
similar to those previously pbserved witn streptothricin. 
These reactions manifested themselves in mice as increased 
activity, severe dyspnea, and in some cases death from respir-
atory failure. The use of purified preparations eliminates 
all of these untoward effects in mice, together with the 
blood pressure lowering errect sometimes seen in rabbits •. 
It is thQUgFt that these toxic reactions are caused by a 
histamine-like impurity present in some batches of strepto• 
mycin. No d~layed lethal effect similar to that of strep-
tothricin has been observed. 
Molitor and Mushett (43) have de·scribed a second type 
of toxic reaction which followed streptomycin administration 
to monkeys. This consisted of a fatty infiltration of 
the liver and kidneys and which gradually disappeared after 
administration of the drug was stopped. The results of 
lidney and liver function tests and of hematologic exam-
inations indicated only minor and transient deviations 
from normal values, and all of the animals seemed to re-
main in good health. No corresponding untoward effect 
could be detected in rats. 
Tests for cytotoxicity of streptomycin have been per-
formed by Dr. D.H. Heilman, using the technic of Herrell, 
Heilman and Gage; concentrations of 1:4000 were £ound to 
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have no effect, while a 1:2000 preparation was interpreted 
as causing "slight decrease in migBation of macrophages or 
a moderate .i.nhibition of fibroblastic growth or both". 
Thus it appears that streptomycin has the same low degree 
of cytotoxicity as penicillin (15). 
Absorption in Man: Oral administration of streptomycin 
on dosage as high as four million units per day rarely 
produces appreciable blood levels, al~hough levels of one 
to six units pernn~. have been reP-orted following oral ad-
ministration of one million units per day (21 261 94,531 10). 
Sine~ active streptomycin can be recovered almoBt quanti-
tatively in the stool, thi~ failure of ~ppreciable absorp-
tion is not due to destruction of the drug in the gastro-
intestinal tract. In contrast to penicillin, streptomycin 
has been shown to withatand the action of gastr~c juice 
containing HCl with no appreciable loss in activity (2). 
A single intravenous injection produces an immediate 
high serum level of streptomycin which_ decreases rather 
rapidly during the first hour after injection, and more 
. -~ - - . 
gradually during the succeedin~ hours. 'The exact_le~els 
encounter~d are illustrated in Figure_!, taken from there-
cent paper by Anderson and Jewell (2).\ It is instructive __ / 
to note that ll-12~hours after single intravenous doses 
.of 20~,~~ and 6oo,~e units, serum levels of 1 to 2 an~ 
3 units per ml. respectively were found (11 2). 
- . 
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Intermittent intravenous.adminrstration every three 
.~ours results in somewhat higher serum levels than cor-
- ~ 
responding single doses1as illustrated in Figure 2.j This 
- __ ...,.,_ 
can be attributed to accumulation of streptomycin tn the 
body (2). In one case, when lOO~~units were given 
every three hours for three doses, serum levels of 3, 1.5, 
31 31 and 1.5 units per ml. respectively were found 1, 3, 
I 6, 9, and 12 hours after the first dose (26). 
As might be expected, continuous intravenous infusion 
produces cmnstant high serum c4ncentrations, the admin~ 
t\r'6..1M~ . 
istration of three mfllion units per day yielding levels 
of 2o-6o units per m1~94). On theoretical grounds, this 
seems to be the most satisfactory method of administering 
streptomycin (26). 
Intramuscular injection of single doses produces a 
slower rise in serum concentration than intravenous in-
jection, the maximum level being reached in 2-3 hours. 
After the peak level has been reached, persistence of the 
drug is similar to that following intravenous administration 
(see Figure 3). In some cases, drop in serum concentration 
following intramuscular injection is appr.eciably slower 
than after equal dosages administered intravenously (1). 
Intermittent intramuscular administration produces 
blood levels comparable to those achieved by intermittent 
intravenous administration, (Table 7)~ and is~robabl!.~~ 
the method of choice at present. In one case, injection 
of 100,e~ units every three hours for three doses gave 
serum levels of 1.5, 1.5, 31 31 and 1.5 units per ml. 
1 
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respectively 11 31 61 91 and 12 hours after the first 
. 
dose1 while in another instance, the levels 9 and 12 
. . 
hours after injection were 1.5 and 0 units respectively. 
Subcutaneous injection of ~treptomycin in single 
doses or intermittently produces results similar to those 
obtained by the intravenous and intramuscular rounes. 
L!s illustrated in ta~le ~ blood levels are comparable 
to or even higher than those found with the latter methods. 
Adequate antibact~rial blood levels can be obtained by 
the subcutaneous administration of 1001~~units every 
three hours. 
Intrathecal administration of streptomycin in single 
~ ~ doses of 5,~ to 201~&units along with intramuscular 
injection of 3001~ units every 12 hours has been found 
to produce spinal fluid levels of from 5 to 14 units per 
ml. and serum levels of 1 to 4 units per ml. at the end 
of 24 hours,2). Single doses of 5o,603 to lOO,~units 
intratheeally yield concentrations of up to 50 units per 
ml. after 12 hours. It appears that antibacterial con-
centrations of streptomycin are maintained in the spinal 
fluid for at least 24 hours after intrathecal administra-
tion of therapeutic doses,26). 
Nebulization of streptomycin into the tracheobronchial 
tree produces no apprecialle absorption, as illustrated 
by the finding that the drug was not detectable in the 
~~~ 
blood serum after administration of up to one-half m~l~en 
units per day in this manner (29). 
0 
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Investigators at the ~eth Israel Hosp~tal in Boston 
have administered stfepto~cin via the intraperitoneal 
Doute in cases of peritonitis ~ith what appear to be 
satisfactory therapeutic results. Serum levels were not 
determined. 
Diffusion; Following parenteral administration, 
streptomycin is widely distributed in the various body 
fluids and tissues. 
Repeated intramuscular or subcutaneous administration 
mq' ~ 
of 501 0SG to 6o,eee-un±ts of streptomycin or subcutaneous 
administration of a sing~e dose of 2001 ~unit~ has been 
found to produce no detectable levels of streptomycin in 
. . . 
the spinal fluid(26). With larger doses of one to three 
~~!~in~ramus~ularly~ levels of one to f~~e 
units per ml. have been obtained. In general, large 
parenteral dosage of streptomycin in the presence of 
meningitis produces spinal fluid levels about one-fifth 
those found in the serum at the Salle time { 26). Diffusion · 
of streptomycin tn either direction across the blood 
brain barrier is normally minimal, and only slightly great-
er in the presence of meningitis. From these data, i~ is 
apparent that effective therapy of meningeal infections 
requires the intrathecal administration of Btreptomycin 
t 
(along with intramuscular or intravenous therapy, in 
most cases). 
~ 
Following single intravenous doses of 6oO,OGG=un~ts1 
streptomycin first appears in the peritoneal fluid in one-
half hour, and then increases in amount while the blood 
0-
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level ~ :ils decreasing. 
"~( .. 
With doses of 125,oee~s ~~tra-
muscularly every third hour, the peritoneal fluid level 
was found to be 23 units per ml. and the blood level 15 
units per ml. at the end of 24 hours. After larger_ doses, 
blood and peritoneal fluid levels were found to be about equal 
(94). 
Relatively high concentrations of streptomycin, even 
higher ·than the blood levels in some cases, are produced 
in the pleural fluid, particularly after intramuscular 
administration (94). 
According to Leopold, streptomycin penetrates both aqueous 
and vitreous humors after intravenous, intramuscular, and 
local administration (94). 
After'' intravenous ar intramuscular administration or 
streptomycin to the mother, the drug has been found to 
traverse the placenta and enter the fetal circulation and 
amniotic fluid in appreciable concentrations (941 26). 
Upon autopsy of two treated patients, Adcock found 
traces to several units of streptomycin in the heart 
. 
muscle, brain and liver (1). ths ~s<;A.th \l44,c.ah.. i(.<.G.t- ~~,to~~ 's --~k .J1 ' ·'-'-- ..,: ..Lu..c.. •-1 · J... "-VktUtLV' C(.IM"""~ o...lf'£. !...CA.vt.JJ.. lVI t'(.t.~ ( l..u~ ~ Vl~ Co~C.t-11\."fTIM ...... (N.. liNI: ..... ~---., \ GiAc.6 "fiMV' ~ J-
~:PV.(lt. ~'\.. '9\"t.l.~'Y\ ~<1 \wtr eo-HQ.\W' 'P"'a.chc~ ~cw.£. 
UrinBrY Excretion: After parenteral administration pf 
streptomycin, excretion proceeds largely via the kidney, 
less than 2 ~ being present in the feces. Usually max-
imum excretion in the urine occurs during the £1rst four 
hours after single doses, one-fifth to one-third being ex-
creted between the fourth and twelfth hours, and only small 
amounts after 12 hours. Traces of the drug are detectable, 
however, for 24 to 30 hours after single injections, and 
up to 72 hours after prolonged dosage of streptomycin 
~ with stDrage of the drug in body tissues (21 10). During 
c:) the first two hours after injection, 20 to 35 per cent of 
the drug can usually be recovered fiom the urine, and by 
the end of twelve hours, 50 to ~ per cent has been ex-
creted (11 21 53). The total amount of streptomycin recovered 
from the urine during the first 24 hours after single par-
enteral doses ranges from 15 to 89 per cent, averaging 53 
to 66 per cent, and varying directly with the urine volume. 
(11 94). Since a total of approximately 55 to 68 per cent 
of the drug is excreted (66 per ceht in the urine and 2 
per cent in the feces) during the first 24 hours after 
single parenteral soses, and only traces are present in 
nhe urine after this time, it appears that some of the 
" 
streptomycin is either stored or destroye~ in ~~e-~od~~-
F Bollowing oral doses of streptomycin as high as four 
- .. .i ~ 
milli?n units daily, only traces of the drug (0.2~0.5 %) 
are found in the urine (1,53). 
As might be inferred fro~ the a~ov~ _da~a, high c~n~ 
centrations of the drug are present in~~~ ~~i~e_f~llow-
'j 
ing parenteral administration. Ziatel and co-workers (94) 
have reported urinary levels of 353 and 16 units per ml. 
respectively 3 and 24 hours after a single injection of 
6oo,Qoo units. Helmholz (30) found concentrations of 
1,131 to 11 330 units per ml. in the urine of a patient 
who was receiving two million units per day for several 
---0 weeks. 
0 
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Fecal Excretion: The lack of appreciable blood levels 
of streptomycin following oral administration, together 
~ with the scanty fecal excretion of the drug following par-
e=) enteral injection indicates that diffusion through the 
wall of the gastro•intestinal tract is limited in either 
direction. Concentrations o£ only 100 to 130 units per 
g~am of feces have been reported fo~low~ng intravenous ad• 
ministration of four.million units per day (10); this 
amount was sufficient, nevertheless, to free ~~~ feees of 
typhoid fever patients from ~ typhosa. 
Administration of streptomycin by the oral route 
results in almost total excretion in the stool, producing 
concentrations as high as 211 000 units per gram of fresh feces 
with a daily dose of four million units. As might be ex-
pected, E& typhosR was completely eradicated from the stools 
of typhoid fever patients, ~ £2!! and the rest of the 
bacterial population greatly reduced, and the fecal odor elim-
inated {531 10). 
Biliary ExCretion: The studies of Heilman and co-
workers (26) indicate that streptomycin is concentrated 
and excreted in the bile. They found th~t two hours after 
starting intermittent subcutaneous administration of the 
drug1 the bile contained about twice as much streptomycin 
as was found in the blood serum. On the other hand, 
Zintel ~ g! (94) found maximum levels of 3 to 7.5 units per 
ml. in th~ bile of patients with blood levels of 18 units 
~ pe~l. after a si~gle intravenous dose of 6001 000 units. 
0 
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Of one million units given intramuscularly to one patient 
in eight doses over a period of one day, the 24 hour out-
put of streptomycin in the bile Was 31 500 units. Further 
study seems necessary before the quantitative aspects of 
biliary excretion of streptomycin can be established. 
Tht:s t c::tdu. ·l ~tA.c.C::.ai't. 'tG-.o.k 
trf n o 1/o.C.,.L 1M. a.cu.h. c.(c..., ~~ stvJis 
~d)_ ~'I 'WA-C.. I S ( .Yl c <. J'1.- L 
l.i,... ~t-s&. Gq..S~S· 
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Toxicity: In the vast majority of oases, streptomycin 
seems to be free of serious untoward effects even when 
administered in fairly'large doses over extended periods of 
time. As yet, no case has been reported where toxie reactions 
were severe enough to warrant the discontinuation of treat-
ment. 
The study of the toxicity of streptomycin as well as 
its therapeutic administration is complicated by the 
impossibility of predicting the toxicological pfoperties 
of various lots of the drug in man from either their anti-
bacterial potency or their acute toxicity to experimental 
0 
animals. Thislack of correlation is apparently due to the 
fact that the morbid and lethal toxicities of streptom¥cin 
do not arise from the same causes, and that only the morbid 
type of toxicity &ccurs in man(44). 
With certain impure preparations, intramuscular or 
subcutaneous administ£ation occasionally produces local 
pain or a burning sensation of short duration at the site 
of injection. These symptoms usually disappearcwithin 15- to 
30 minutes, but are sometimes followed by soreness which 
persists up to several hours(2); they do not occur when 
crystalline preparations of streptomycin are used~ When the 
intravenous routeais employed, local venous irritation is 
occasionally observed, but thrombosis is rare. 
According to Hinshaw and Feldman (34} streptomycin may 
have a neurotoxic effect after prolonged administration of 
large doses. This neurotoxic effect seems to involve the 
~·~hi-h r'lz..rVi:. , ~""'"' \'V'lo.vnft.-s~ rtsl'lf o.s tra.Vlsd:nt- d£a.fV\.£SS' or 
A.•s·lu:rb(A.rtt.~ at Vt.~hbu..La-r fW.-'ch~m \.\n+h. WtttrKul ve:rtlc_}O · 
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The commonest group of untoward reactions occurs when 
a histamine-like substance is present as an impurity. This 
consists of a throbbing headache and a flushing of the face, 
and sometimes nanaaa, malaise, vomiting, skin rash, and muscle 
and joint pains. Drug fever may occur two or three days 
after treatment. All o~ theseeffects may be largely avoided 
by slow intravenous infusion of the drug(2, 82, 26). 
Chills and fever, described as similiar to the reaction 
following administration of pyrogen-containing penicillin 
preparations, have been noted (26). 
Cutaneous toxic reactions vary from urticarial eruptions 
and toxic erythema to severe dermatitis (26). 
Repeated intnamhaaal injections of streptomycin in 
doses up to 100,000 units per day have been reported with 
no evidence of meningeal irritation or other untoward 
reactions (86). However in one case there occurred an 
i~ediate reaction consisting of generalized spactieity and 
trembling, and reduction of the res~~toryvrate to four per 
minute. The patient was said to have the appearance of 
''impending disaster", and respirations did not return to 
normal for 15-20 minutes. Although intramuscular imjection 
of the same preparation of streptomycin caused no untoward 
effects, ·the reaction was attributed to it smnce a control 
intrathecal injection of sterile physiological saline 
solution had no effect. Apparently this represents either 
a toxic response to an impure preparation of streptomycin 
0 
0 
0 
\0 
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I 
-41-
or a case o~ indimidual idiosyncrasy on the part o~ the 
patient(l6). 
Another unique toxic reaction has been observed in 
two cases ~allowing the intraperitoneal administration of 
1,000,000, units of streptomycin. This consisted of· 
dyspnea, cyanosis, Cheyne-Stokes respiration~ tachycardia 
of over 200 per minute, and rapid ~all in blood pressure to 
shock level, approximately 15 minutes after the drug was 
injected. Intravenous injection of ~drenaline dramatically 
restored both patients tolitheir pre-streptomycin condition, 
. 
with no discernible after effects. This reaction may be 
attributed to the .aforementioned histamine-like impurity, 
which is known to have been present in the preparation of 
streptomycin used (60). 
Carefully conducted renal function tests and blood 
chemistry stu1ios during and following the administration 
of streptomycin preparations of varying degrees of purity 
have consistently failed to reveal any con9lusive 
evrdence of significant renal function impairment. Although 
renal irritation may occur, as indicated by the occasional 
finding of proteinuria and microscopic hematuria, 
permanent renal damage was not detected even with amounts of 
streptomycin greater than the contemplated average therapeutic 
dose (26,94). 
Although fatty metamorphosis of the liver of monkeys 
treated with streptomycin has been reported, there i~ no 
0 
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reason to believe that this occurs in man, or that it leads to 
permanent liver damage when itrdoes occur. The usual clinical 
and laboratory tests of hepatic function give values within nor-
mal limits during and after treatment with streptomycin ( 26., 94, 34) 
No evidence of damage to the hemopoietic system was detected 
on the basis of erythrocyte, leucocyte, platelet and differential ~ ~ 
white counts, hemoglobin 1 deter.minations, and blood smear examinations 
(26,94) 
Thus far, no serious or uncontrollable toxic reactions to 
streptomycin have been reported; it appears that pure crystalline 
preparations of the substance are of the same order of toxicity 
as penicillin, J 
0 
0 
0 
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Dosage and Methods of Administration: Insufficient 
ciimical data are available at this time for dogmatic 
. 
statements concerning the optimal dosage and modes o£ 
administration of streptom~cin tp be made. Certain genM 
eralizations and preliminary recommendations are, however, 
warranted. 
~he optimal dosage and route of administration depend, 
among other things, on the location -and accessibility of 
the infection, thepresepce of possible streptomycin•inactiv-
ating factors in ~e body, and the susceptibility of the 
etiological agent. As a guide to therapy, it appears that 
occasional determinations of the sensitivity of the path-
ogenic organism should be made before, du:r1ng1 and after 
!!./ treatment. t/1'7 
At pEesent, the preparations of streptomycin in gener-
al use are the hydrochloride and sulfate salts, dispensed 
as fine, dry powders in ampules containing bne million or 
mor~S units. It is probable that future chemical studies 
ana synthetic procedures will yield pharmaeolo~ically 
superior streptomycin derivatives, especially with respect 
to activity and rate of excretion. 
For intermittent intramuscular administration, it is 
recommended that one or two cc •. of physiologic saline solu-
-{o ns ~ .. 
tion containing 1251~un~ts-per cc. be ~nJected every 
three or four hours.v</~ some cases, injection of two to 
four ce. of a similar solution may be made every six hours, 
with satisfactory clinical resu~ts (32). If the continuous 
intrgmuscular technic is employed, the proposed daily dose, 
usually one to two mill!~ units~ may be given over a 
c:J pe~iod of 24 hours in 500 to 1000 cc. of physiologic saline 
0 
0: 
solution (32) • 
Satisfactory results may be obtained by the subcu~ 
taneous administra[on of strept9mycin in accordance with 
the method recommended for the intramuscular route. So~u-
u,g fe t75''"1 
tions of 1~0,000 units per cc. may be used (32). The 
writer believes that this method has certain advantages 
over the intr~usculat route from the point of view of ab-
sorption and ease of administration, and recommends that 
it be used more widely. The disadvantage of local pain at 
the site of injection can be eliminated by the use of high-
ly purified preparations. {ot b., cuJ.d.;f~ ~ Pt-o&G..ln.t). 
The intermittent intravenous method of administration 
is not recommended, since it has no advantage over the inter-
mittent intramuscular and subcutaneous methods. For cont~n­
uous intravenous intravenous infusion, the proposed daily 
' dose of from one to four million units may be dissolved in 
two liters of physiologic saline solution and given at a 
rate of about 25 drops per minute (32). 
For the treatment of meningitis, 25,000 to 1001 000 
units or· streptomycin in 5 to 10 cc. of physiologic sanne 
solution may be given intrathecally at intervals of 24 to 
48 h . (32 86) FDY P"L5f ru~r+s \11\.tLrmrift.\'\,T l~-h'a.VHA.4oSeiA.I~r ours 1 • . . ~ ~ +"- '\.YA.f '1 ~hs"'-'ct.. IGI~ q t,~f."'- a.L(J"IIt.<; ort.t" L ""+rc. ~ i.r~'\ . 
Streptomycin may be administered intraperitoneally for 
the traatment of peritonit~s by instillation of one million 
units in 1000 cc. of physiologic saline solution.(60). 
0 
0 
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Intramuscular administration seems to be effective in 
the treatment of peritonitis also, as might be expected 
from its diffusion into the peritoneal fluid. (32). 
Oral administration would appear to be of v.alue 
as a preoperative measure before surgery of the gastro-
intestinal tract, and in conjunction with parenteral 
administration for the treatment of combined intestinal 
and s~stemic infections such as typhoid fever. Amounts 
as high as i to four million units daily may be given in 
four or more divided doses (321 73). 
For treatment of inf"ections of the larynx and trachea- _; 
bronchial tree1 physiologic saline solutions of s~repto­
mycin containing 251 000 to 501 000 units per cc. may be 
nebulized and inhaled in total doses of up to 5001 000 
units dail~ (32). 
. _ Jo1oo0_ 
Streptomycin in concentrations of 250 to~units 
per cc. may be used for topical applications. 
I'V'\-tYa. ph .. \A.Y()..( 1 ~Sh!-kc.Ju·;, I~ ~r. Y• t.V·h.. c1b ~c;'i.,. 
~ V' ~5 1 ~ p li.u.nt..., a. I +tt." "'1 ~ ~'-1"' ( u.r-L-t s a...t-t. 
t>bt'a-~t~'UA t't.t ~'i ~1-sc.c,~ ~ ~~ ., .,_~ec.J.· v 
().&, LM L lilt ~/yc.vh,{v,. . 
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VII, _ ActivitY in Vitro 
The chief objective of !n vitro testing of an antibiotic 
agent is the characterization of the substance from the point · 
of view of selective antibacterial activity, as one of the pre-
liminary steps in evaluating the agent before clinical applica-
tion. The l~itations of this method are well illustrated by 
the fact that penicillin has been found to be therapeutically 
effective in infections by certain organisms against which in 
vitro tests indicated that it was ineffectual or onl~ slightly 
aetive (31). 
The exact mechanism of action or streptomycin is not yet 
known, but several interesting characteristics of the action 
of antibiotics in general and of streptomycin in particular have 
• 
been discovered. Antibiotic substances act by interfering wi~h 
certain vital metaboli¢ processes of bacteria; this may con-
sist of a chemical reaction with an essential substrate or en-
zyme system, an effect upon the surface tension of the organ• 
ism, or interference with the prodesses of respiration or bac-
terial cell division (74). 
The fact that streptomycin is inactivated by certain 
sulfur-containing organic compounds, together with the demon-
stration that the sulfhydryl group is nec~ssary for cell pro-
lifer~tion (Hammett, quoted by Cavallito (5)) suggests that 
streptomycin may act by interfering. with the sulfur metabolism 
of bacteria, or more specifically, with the process of cell 
division. This hypothesis is supported by the finding that 
~ the majority.of cells exposed even to dilutions of streptomycin 
0 ~reater than the mintmal inhibitory dilution undergo elongation, 
0 
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indicating interference with the process of cell division (59). 
However, since .streptomycin has a definite bactericidal action, 
and even a marked bacteriolytic effect against certain organ~ 
isms1 it is probable that other mechanisms are also involved. 
Furthermore, it seems likely that the precise mode o£ action 
is_different for different bacterial strains, and varies with 
the relative concentrations of the antibiotic substance and the 
bad~ermal inoculums1 as well as with certain experimental con-
' 
ditions. This is well illustrated by the finding that strepto-
mycin eauses lysis of living ~ subtilis cells, and has no effe~t 
upon dead ~ subtilis eells or living ~ aureus (78). v~uf 
The presence of resistant organisms does not alter the 
antibacterial action of streptomycin on susceptible organisms, 
and the substance is not destroyed or absorbed by either resist-
-
ant or sensitive bacteria(78). 
~he gram staining reaction appears to be only one of the 
properties of specific vacteria which point to differences in 
susceptibility of the bacterial cell to streptomycin (and other 
antibiotics~. Further study of antibiotic action on bacteria 
will_undoubtedly contribute to a better understanding of the 
biochemical constitution of the bacterial cell. 
- The development of resi~tance to streptomycin on the part 
of preyiously susceptible organisms expose~to the substance 
has occasionally been observed (80, 32).~v1This process of 
adaptation has been attribute~ to an actual modification o~ 
the individual bacterial cells, together with a process or 
natural selection (491 80) 1 and may be permanent of reversible 
!:) (Hinshelwood1 quoted by Waksman 80). f'rable 9 illustrates the 
<:) maEked bactericidal action or streptomycin on susceptibl:J 
0 
0 
0 
0 
strains (W11 W2) or~. vulgaris, as well as the pronounced re-
duction in its activity against a resistant strain (R) or the 
same spec~~ Investigation of the morphological and physio-
~
logical changes associated with the development of resistance 
may throw light upon the fundamental mechanisms or action of 
streptomycin. 
It is interesting that while a strain which has developed 
resistance to one antibiotic agent may also be resistant to a 
closely related agent, it is not resistant to a different type 
or antibiotic (80). 
({{To w3at extent the factor or resistance will complicate 
the problem or therapy is not yet clear. 
The original report of Schatz st 41 (61) announcing the 
discovery or streptomycin characterized the substance as having 
considerable selective antibiotic activity against gram-negative 
as welVas gram~positive bacteria. These observations were 
soon confirmed and extended by Robinson and co-workers (59) 1 
who emphasized the activity of streptomycin against organisms 
or the colon•typhoid and Sa1monella groups. Simultaneously, it 
was demonstrated that streptomycin was the most effective anti-
biotic agent of a group tested against !£ tuberculosis by ~ir­
tue of its highly bactericidal action !n vitro, its 1n vivo 
activity, and its relatively low toxicity (62). Subsequent 
!n vitro studies have revealed that streptomycin has an 
amazingly wide range of antibacterial activity; ~ong t~e 
organisms which are notably sensitive to it are the entire 
group of Enterobacteriaceae, including Aerobacter, Escherichia, 
Klebsiella,_ Sa1monella,_Eberthella,_and Shigella; the Proteus 
~ 
8 
0 
group;~. aeruginosa; Hemophilus yertussi~_and li£ influenzae; 
the' Pasteurella group; the-Brucella group;~ diphtheriae; EI 
anthracis; the R~ subtilis group; and the Mycobacteria, includ-
ing the human strain of ~. tuberculosis. In addition, strepto-
mycin has been found to be active against a mixed culture of 
Pr. vulgaris and an anaerobic streptocoecus(75). The effect 
of streptomycin is limited against anaerobic spore-formers 
and fungi (59), and it has no influence on the toxicity of tet-
anus toxin (461 95). No information has yet been reported to 
indicate that it is effective against viruses. 
The currently accepted antibacterial spectrum of strepto-
mycin is presented in table 101 taken from a recent paper by 
Waksman (82). Sev~ral explanatory remarks and comments are 
helpful in interpreting this table. The relative values for 
the activity of streptomycin against the organisms listed can 
be taken as only approximately correct, since the determina-
tions were made by several investigators working more or less 
independently and using different a9say methods. In addition, 
it should be borne in mind that different strains of the same 
bacterial species have been found to vary as much as a 
hundred-fold or more in·their sensitivity to a given prepara~ 
tion of streptomycin (80,82). 
It is of interest to noteethaithe list of organisms 
susceptible to streptomycin includes most of the organisms 
which are resistant to penicillin. Evaluation of the sig-
nificance of this observation with tespeet to therapy must 
-
await the results of clinical trial of streptomycin against 
<:) each of these organisms. 
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VIII. Activity in Vivo 
Animal experimentation has been repeatedly demonstrated 
to be an excellent proving ground for the evaluation of agents 
prop•sed for the treatment of human infectious disease. In 
general, results of animal expertmentation have correlated 
rather closely with clinical results in man, insofar as ac~te 
infectious diseases of bacterial origin are concerned. With 
diseases of a chronic nature and those in which the experiment~ 
al disease differs from the naturally occurring human disease, 
(such as tuberculosis), correlation has been less close. All 
things considered, well executed animal experimentation is the 
best method available for selection of new drugs for clinical 
trial in man. 
Early in vivo studies (38) indicated that streptomycin 
was capable of protecting experimental animals against lethal 
doses of var~ous pathogenic organisms. Using crude prepara-
tions of streptomycin containing 30 units of the active sub-
stance per mg.~ it was found that micewttgh1ng 18-20 gr~s 
eould be completely protected against lethal infections due to 
- -
Salmonella ·schottmfilleri with 6.4 mg (190 units) of the ma-
terial. For prGtection agains~ £2. aeruginosa, 6.4 to 12.8 
mg were required. In doses of 150-300 units1 streptomycin 
was found to afford complete protection to 11-day-old chiek 
embryos infected with fowl typhoid (Shigella gallinarum) and 
B. abortus. The same preparation was also effective in pro-
tecting experimental animals against~. vulgaris (38). 
0 
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Later animal studies have demonstrated that streptomycin 
is capable of controlling exp~rtmental infections by the more 
resistant gram-positive organisms D. nneumoniae and g. aureus 
c:) (59). Also, complete protection of experimental animals against 
lethal infections by a mixed culture of £t. vulgaris and an 
anaerobic streptococcus was obtained with adequate doses of 
0 
0 
a crude streptomycin preparation (75). 
The administration of 11 000 units of streptomycin per 
day in-divided doses was found by Hei~an (27) to completely 
protect mice against lethal infections with Pasteurella 
tularensis. Furthermore, the organism was completely erad• 
icated from the spleens of treated animals as determined by 
cultural and animal inoculation methods. These results were 
interpreted as suggestiv~that streptomycin may be of use in the 
treatment of tularemia in man, a widespread disease of high 
morbidity and for which there is no satisfactory therapy at 
, present. 
Additional studies by Heilmen £28) showed streptomycin 
to be notably effective in protecting mice against le,thal 
intr~-abdmminal injections of three different strains of 
~lebsiella when administered in doses of 185 to 500 un~ts. 
-per day for 2 to 3 days. With mice intranasally infected 
with a type A strain of K. pneumoniae1 administration of 500 
units of streptomycin per day for 3 days had only a slight 
protective effect, but prolonged the life of infected animals 
considerably. When treatment was continued as above for 7 
daya~~the mortality was reduced from 100 per cent to 13 per cent. 
0 
0 
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In a study designed to compare the relative dffects of 
streptom~cin and penicillin in the treatment of the spiro-
chetal infections relapsing fever and leptospirosis ictero-
-
hemorrhagiae1 Heilman(29) infected 100 mice intra-aBdomin-
ally with citrated rat ~or mouse blood containing large numbers 
of virulent Borrelia novyiJ Half of the animals we~e treated 
by subcutaneous injection of 1 1 000 units of streptomyc~n per 
day in divided doses~ starting the day after inoeulation1 and 
the uther half served as untreated controls. It was found that 
, the blood of treated animals became free of spiroch~tes con-
, siderably faster than that of untreated controls. Four (8~) 
of the treated mice dies1 while of the untreated, 10 (20%) 
died. In a similar experiment 1 using hamsters infected 
with ~ ieterohemorrhagiae1 25 treated animals remained well1 
whereas all 25 untreated controls died. Attempts to demonstrate 
~ep~ospira in the livers and kidneys of the treated animals> 
by guinea pig ineculation were unsuccessful. On the basis of 
these and further similar experiments., it was concluded that 
streptomycin exerted considerable protective effect on ex-
perimental infections due to ~otrelia novyi and Leptospira·. 
~cterohemorrhagiae, but was not as effective, unit for unit1 
as penicillin under similar circumstances. Since, as has 
already been pointed out, the unit of penicillin represents 
a much larger amount of antibacterial actiwity tha~ the unit 
of streptomycin., the latter conclusion soes not indicate that 
s1treptomycin vrill necessarily be relega~ed to the position 
o£ an adjunet to penicillin &n the treatment of spirochetal 
t:) infections in man. 
() 
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Hegarty (24) has reported that streptomycin is effect-
ive in vitro and !n Vivo against HemophilU§_pertussis. He 
found that 3 units per ml. produced definite inhibition of 
growth, while 15 units per ml. was bactericidal. Fifty per 
cent of mice infected with 51 000 uells were protected by 
21 000 units of str·eptomycin daily for 10 days, and the sur-
vival time of. those that died was extended to 22 days as 
compared to 5! days for untreated controls. 
Seeler ~ A! (64) studied the effect bf streptomycin on 
on avian malaria. It was found that the frug was ineffective 
in reducing the per-centage· of parasitized erythrocytes at the 
peak of trophozoite-induced Plgsmodiym cath~erium and ~ 
lophurae infections of Pekin ducklings and ~ ~alli~ceum 
infections of whtie leghorn chicks.i:nin single comb white 
leghorn chicks infected by intravenous inject~on of f· 
.. 
galljnace~ sporozoites, streptomycin in doses of 4001 000 
units per Kg. per day reduced the percentage of parasitized 
erythrocytes to one-hal~ that in untreated controls. Sulfa-
diazine and quinine were found to have much more suppressive 
effeet than streptomycin •. 
At the suggestion of Dr. Waksman, Feldman and Hinshaw 
of the Mayo Clinic set about to determine what effects, if 
any1 streptomycin has on the pathogenesis of experimental 
tuberculosis in guinea pigs. Their preliminary experiments (14) 
demonstrated that streptomycin treatment, started at the ,time 
of inoculation of the animals with a virulent human strain of 
m. tubercylosis, was capable of a striking suppressive effect 
on the development of the disease. 
0 
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Later experiments (141 15) were designed to test the 
ability of streptomycin to control well established tuberculosis 
i~ guinea pigs, by delaying treatment for 15 and 48 days after 
infeetion. I~one study, 49 guinea pigs were used, 25bof them 
receiving 6~000 units of streptomycin daily in four divided 
doses, and the remaining 24 serving as untreated controls. 
Biopsy of the liver was done on all of the animals one day 
-
before treatment was started (47th &a¥ of oiseaset so that 
an estimate of the state of infection prior to treatment was 
available. When, after 166 days of treatment, the experiment 
- -
was terminated, only 2 (8%) of the treated group Bh& died, as 
compared with 17 (70%~ of the untreated group. At necropsy, 
most of the untreated controls showed severe, widely dissemin-
ated parenchymal tuberculous infection, with grossly detectable 
lesions of the spleen, liver, lungs and tracheobronchial lymph 
nodes. On the other hand, the treated animals showed no evi-
dence of widespread tuberculosis, except in the case of one 
animal which died after 98 days of treatment~ only 4 of the 
25 animals showed gross involvement of the organs of predilection. 
The average numerical index of infection as determined by an 
arbitrary method proposed by Feldman (13) 1 was 80.4 for the 
untreated controls and only 1.24 for the treated animals. 
Liver biopsy revealed that the destrueti•e necrotizing lesions 
present before treatment was started werqresolved completely 
or converted into atrophic remnahts. However, 15 of 23 spleens 
removed from treated animals were demonstrated by inoculation 
tests to contain virulent organisms. Tuberculin sensitivity 
c:J was greatly redueed in 14 of 23 treated antmals, and ~as absent 
0 
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in the remaining nine. It appeared that streptomycin exerted 
bactericidal as wel¥as bacteriostatic action against M· 
tuberculos!§, even though the schedule of treatment was such 
that the treated animals were devoid of the drug during about 
one-half of each 24 hours. It was considered the results of 
these experiments were sufficiently impressive to warr~nt clin~ 
ical trial of streptomycin tn the treatment of human tuberculosis~ 
even though experimental tuberculoses in guinea pigs differs 
in so many respects from naturally occurring human tuberculous 
infections assto constitute an essentially distinct disease. 
Results similar to those of Feldman and Hinshaw were ob-
tained by Youmans and McCarter (92)93), who studied the effect 
of streptomycin on tuberculous infections in mice producetl by 
M£ tuberculosis X!r• hominis. ~view of the fact that mice 
are much more resistant to tuberculosis than guinea pigs, 
and since the infection in mice is primarily pulmonary, it 
was suggested that these results might be more nearly anal~ 
ogous to those which would be obtained in the treatment of 
human tuberculosis. However, to attempt to predict~the latter 
on the basis of animal experiments is treading dangerouiy 
close to the realm of speculation. 
Smith abd McCloskey (66) have compared the relative effects 
of streptomycin ahd promin in the treatment os experimental 
guinea pig tuberculosis, and have confirmed the generally held 
impression that the former is far superior to the latter with 
respectto both efficiency and non-toxicity. More specifically, 
the chemotherapeutic index of streptomycin was found to be 
~ more than 10 times that of promin, which has hitherto been 
0 
comsidered the best chemotherapeutic agent for the treatment 
of experimental tuberculosis. In addition1 the simultaneous 
administration of streptomycin and promin produced results 
<:) considered to be much better than those obtained with either 
agent alone. Not only did the administration of ~treptomycin 
potentiate the action of promin~ but it also reduced the anemia-
producing tendency of the latter, and allowed higherOlood levels 
to be obtained. The chemQtherapeutic e~ficiency of th~ combined 
method of treatment was found to be almost three times as 
0 
0 
great as anticipated from simple summation. ~The authors re-
commendcautious application of the combined streptomycin-
promin treatment in properly selected clinical cases. 
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IX. Clinical Reports 
Largely as a consequence of the limited supplies of 
st~eptomycin a~ailable, elinical expierience with this a~ent 
has been rather meager, a total of about 100 cases having 
I 
thus far been reported in thecliterature. 
!YPhoid Fever: The first report on the clinical use Of 
streptomycin was by Reimann et al (53),who treated ~ive cases 
of typhoid ~ever with streptomycin. In 2 patients there was 
striking clinical improvement after 36 hours to ? days· 
treatment, and it seems reasonable to ascribe the subsequent 
cur~tn streptomycin, since sudden recovery is rare in typhoid 
fever. In at'h31<hi patient recovery was synchronous with therapy, 
and may have been spontaneous or induced by7streptomycin. 
Im a 4th patient oral therapy was ineffective, and inadequate 
0 . 
continuos intravenous therapy later instituted had a 
1\ . 
questionable effect. The ~i~th patient failed to improve in 
spite of the fact that blood levels were twice the amount 
necessary to kill E. typhosa in the test tube. The causative 
-
organism was found not to have become resistant, and failure 
of the drug to sterilize the blood was attributed to in-
adequate dosage or possibly t~ unknown factors in the body 
which interfere with drug action on E.Ti,hosa. TH§ authors 
. 
concluded that although the therapeutic value of streptomycin 
could not be definitely determined from the above five cases 
results were S'trongly suggestive that the drug contributed to 
or actually caused recovery. 
0 
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It was recommended that one to four million units of streptomycin 
daily be employed as a minimal dose tor the treatment of 
systemic or urinary tract infections with !.typhosa. Combined 
oral and parenteral therapy was advised during and after 
typhoid fever and other bacillary infections of the gastre~ 
intestinal or urinary tract to cure the disease, prevent 
reinfection and to avoid the ca~raeteatate. Oral therapy was 
advocated as of probable value for prophylaxis of typhoid fever 
and similia~ infections~ 
Anderson and Jewell(2) and Herrell and Nichols (32) have 
~each reported single oases o~ typhoid fever in which results 
of streptomycin therapy were sugges~ive but difficult to ev-
aluate. A definitive estimate of the efficacy of streptomycin 
in this disease~ must await further study on a larger number 
of cases. 
Gastro-intestinal in~ections: Flippin (18) has successfully 
treated4Salmonella infections o~ the gastro-intestinal tract 
~; 
~ . 
with gtreptomyoin. It is probable that the drug may be of some 
value in the treatment of similiar bacillary infections of the 
' 
gastro-intestinal tract including Shigella dysentery. 
• 
Brucellosis: 0~ five oases of brucellosis treated by 
Herrell and Nichols(32), only one was considered to have beem 
cured by streptomycin. In this case although the drug caused 
repeated sterilization of the blood stream, permanent recovery 
occurred only after the tremendously enlarged and infected spleen 
was removed, For this reason, it is suggested that the advisability 
of considering splenectomy in similiarvcases of chronic 
0 
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brucellosis be determined. In a second patient recovery occurred 
after two course·s of streptomycin treatment, butitt is not 
known whether this was spontaneous or induced by the drug. Two 
ftultcl 
.additional casesAto improve symptomatically although blood 
cultures became negative. The fifth case was not cured, but the 
dosage used·was far below the proba~le minimum therapeutic dosage 
of one million to two million units daily. The;impression of 
the investigators was that further clinical trials of 
streptomycin in acute cases of undulant fever with bacteriemia 
are justified, but that the drug is of doubtful value in chronic 
undulant fever without bacteriemia. Flippin (18) has treated 
acute brucellosis successfully with intra-muscular streptomycin. 
Reimann(54) has obtained encouraging but inconclusive results 
in the treatment of systemic Brucella infections with streptomycin. 
(t 
Bacteremia: Two cases of ~.coii bacteremia originating 
from pyelonephritis were successfully treated by fferrell and 
Nichols(32)'using total doses of 1,000, 000 and 20,000,000 units 
of streptomycin respectivelly, but bacilluria persisted in the 
? 
second case. Cases of bacteremia due to ~ aefgenes, Ps. 
)\. -
>' o/ .; b 
aeruginosa, and mixed Salmonella and Froteus ammoniae infections 
of the urinary tract have been successfully treated by the same 
workers. Deaails of these cases are listed in table XI .. 
...., . 
7 , lc·.-. 
Anderson and Jewell (2} have reported a case of GroupB. Salmonella 
sepsis in which streptomycin treatment Was of doubtful value, 
since the recovery may have been largely spontaneous. In this 
connectio~ it should be pointed out that about one -half of cases 
of bacteremia due to gram- negative bacilli recover without 
treatment. 
0 
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Urinary Infections: The experiments of Helmholz (30) led 
him to conclude that "streptomycin should prove to be the most 
useful urinary antiseptic so far developed". He found that a 
concentration of 100 units per ml. of streptomycin was sufficient 
to rapidly reduce the number of any organisms found in urinary 
infections, and that 235 units per ml., _about one-fifth the 
urinary concentration found wit~e recommended therapeutic 
dosage of streptomycin produced rapid-sterilization of massively 
infected urine. 
The results of theatment of 13 patients with infections 
of the urinary tract are listed in table XII. It wi11 be 
seen that in ten of these cases, the response to streptomycin 
treatment was considered·good, even though several of th~ in-
fections were polyvalent. The investigators found that best 
results were obtained in infections due to Pr. ammoniae or 
A· aerogenes, and that those due to Ps. ~eruginosa and ~ coli 
did not respond as satisfactqrily to streptomycin treatment. 
Of course, the factor of pathologic changes in the urinary 
tract, such as obstruction with stasis must be considered, and 
adequate surgical measures s~ould be ins~ituted for best results·. 
It appears that the optimal daily dosage of streptomycin is one 
to to two million units, and that alkalinization of the urine 
enhances the activity of streptomycin. 
Greey (23) of the University of Toronto has obtained 
results similar to the apove. He found that streptomycin 
was dffective for treatment of chronic urinary tract infections 
owing to such gram-negative organisms as Pr. vulgaris, ~ 
aerogenes,. ~ coli, Ps. aeruginosa and Eberthella sp. 
0 
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Wit~ daily dose of one million units divided into 8 intra-
muscular injections, urinary cultures, become negative 
for Pr. vulgaris in 4 hours, and for coliform organisms in 
3 hours. In one case, E.coli was eliminatedfrom the urine 
after two hours of ~reatment,;Although infections were per-
manent~ly cleared when the urinary tract was normal, damaged 
tracts were found io be readily susceptible~to reinfection via the 
catheter. 
Similiar satisfactory results in the treatment of hereto~ore 
resistant urinary infections have been obtained by the U.S. Army 
Medical Corps, and by the Pratt Diagnostic and Beth Israel Hospitals 
in Boston. ( 60) 
Influenzal Meningitis; Weinstein(86) has treated seven cases 
~f meningitis due to Hemophilus influenzae; 6 were type B and 
the remaining organism could not be typed with either type A 
or type B antiserum. Treatment oQnsisted of intermittent 
intra- muscular administration of 125,000 units of streptomycin 
every 3 hours for seven to ten days, and intra-thecal 
injection of 25,000 units every 24 hours and continued for 4 
to ? days after intra-muscular administration was stopped. 
Sterilization of the ~pinal fluid occurred within 24 to 48 
hours, and all ? oases recovered without complications or 
relapses 
Herrell and Niehols (32) have reported 4 oases of influ~ 
enzal meningitis which were successfully treated with 
streptomtain. Three of the infecting organisms were type B 
-and the fourth was untyped; two of the-patients received 
0 
0 
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other medication in addi thin .to streptomycin. Details of oases 
are given in table 13. Smith abd Birmingham (65) have obtained 
comparable results in the treatment of influenzal meningitis 
. 
with streptomycin. They point out that the organism becomes 
drug fast when insufficient doses are used,~~~ve achieved 
sterilzation o~ the blood and spinal fluid within nine haurs 
after starting treatment with two hundred thousand units 
every two hours. they suggest that the treatment of choice 
will probab1y consist of combined serum and streptomycin, 
sulfadiazine and streptomycin, or all three; the resul tsc·of 
Weinstein, however, indicate that no treatment in addition 
to streptomycin is necessary. The same workers (65) treated 
a single casefof Salmonella meningitis with streptemycin, but 
- \ 
it is not certain what part of ·the drug played in the reoovex~ 
Although there have thus far been no reports concerning the 
treatmeniof !· £Qli meningitis with streptomycin, it appears 
probable, on aatheoretical basis, that the drug will b~ effective 
in this lethal disease for which there has hitherto been no 
adequate therapy. 
In the few cases of tuberculous3 meningitis thus far 
treated, streptomycin has failed to give evidence of amy 
pronounced ~ft~rapeutio effect (65, 16). 
Pulmonary Suunurative Diseaseb Of five oases of pul-
monary suppurative disease(. bronchi8otasis ) due to e;ram.-
w 
negative organisms, stre1tomycin treatment by nebulization 
and/or intramusc~lar injection eradicated the infection in 
four (32}. Irreversible pathologic changes such as 
bronchiectasis and fibrosis were, of course, not benefited.The 
Q details of these oases are listed in table l"l. 
Tularemia: The experiments of Foshay (19) indicate that · 
() P.tularensis is one of the most sensitive organisms to the action 
of streptomycin in vitro. He found that concentrations or only 
a few units peT •1. weTe bacterioidal in a matter of seconds or 
minutes. Whereas the average duration of the untreated disease 
is about four months, seven oases treated with relatively low 
doses of streptomycin were observed to recover promptly. One 
patient was discharged as cured on the seventeenth day of the 
disease, after only 9 days of streptomycin treatment~ Another 
patient with generalized infection of the peritoneal cavity 
and perisplenitis was found to have·noninfeotive peritoneal 
fluid after only 6 days of treatment~ Normally the peritoneal flv,d 
. \ 
is infective for at least 9 months. Streptomycin therefore 
appears to be the most efrective treatment yet developed for 
this widespread disease of high morbidity. 
~eritonitis: Three oases of peritonitis due to gram-
negative organisms have been successfully treated with 
streptomycin ( 60) . In two ofthes·e, additional treatment was 
employed~ and although the results were suggestive, no def-
inite conclusions concerning the value of streptomycin can 
be drawn from these oases. In a single case of E. coli 
peritonitis ( retrocecal abscess ) following rupture of the 
appendix, intramuscular streptomycin therapy combined witg 
surgical drainage produced rapid recovery. Here again, results 
can be considered hardly more than suggestive. j 
0 
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Syphilis: In three cases of early syphili~ treated by 
Harrell and Nichols (32) with inadequate doses of streptomycin 
darkfield examinations were hemdered temporarily negative in 
from 21 to 81 hours after treatment was instituted. Temporary· 
improvement0 occurred in a case of gumm~tous syphilis during a 
short period of treatment with obviously insufficient doses. 
The value of streptomycin in syphilotherapy can not be stated. 
until more oases are treated with adequate doses over an 
extended period of time. 
Wound Infeetions: Howes (37) has sutured at least 14 
wounds with a mixture of 200,000 units of streptomycin and 
5% marfanil without any wound infections or untoward reactions. 
In a case of mixed ~. coli and ~· vulgaris sepsis following 
excision of a large bladder diV-erticulum, surgioa~ drainage 
., 
I 
and irrigation ·of the wounds with a streptoM~cin solution • 
{100,000 units/ 50cc.) produced rapid recovery(60). 
Obviously,accepted surgical princip<~ts must continue to be employed 
even in infections by·rstreptomyain - sensitive organisms. 
Miscellaneous: Table t3 lists several miscellaneous 
' 
infections treated by Herrell and Nichols (32)., ~ogether with 
results of streptomycin therapy. In some of these, the dosages 
used are now~known to be entirely inadequate. In the four 
oases of ozena listed, symptomatic improvement followed treat~ 
ment with streptomycin, but evaluiion of results must wait 
follow-up studies. 
Tuberculosis: Chemotherapy has until very recently 
been disappointing in the treatment of human tuberculosis. The · 
sulfone group of agents have 
I 
0 
0 
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failed to live up to their predicted efficacy on the ba£is 
of animal experiments, largely as a result of excessive 
toxicity in man(35,36). The greater effectiveness of 
str-eptomycin in experimental tuberculosis, coupled with its 
lack of appreciable toxicity, has lil!e.d to the hope that. this 
agent might be the long sought-after ~'cure for tuberculosis". 
Preliminary studies by Hinshaw and Feldman a( 3.4) seem 
to indicate that streptomycin has a limited sujppressive 
effect, particularly on the more '1.~:-.unaB:&al types of ;?rpitlm6nary 
and extrapulmonary tuberculosis. Present evidenee points to 
a bacteriostatic rather than bactericidal) .action, since prompt 
reactivation of infection often follows eessation of treatment. 
No rapidly curative effect was observed in 8 casespf 
pulmonary tuberculosis treated for 8 months.Extensive and 
progressive lesions of known recent origin tended to improve 
rapidly in a manner resembling the natural_healing process. 
This was especially apparent in fjne, widely distributed 
lesions of hematogenous distribution. 
Striking and unmistakable improvement occurred in thee 
X-Ray appearance of the lung lesions in two patients with early 
miliary tuberculosis but no parallel improvement in clinical 
oondi tion was de_teoted, 
Treatment of thej~pyema was irritating and produced 
indefinite or disappointing results. 
In 4 of 5 patients with solitary kidneys and 
tuberculosis of the genito~urinary trac~ treatment caused 
disa:ppearance o:f tuber~~~t>ael~...uJ;i 
0 
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from the urine within 2~4 wee~s of streptomycin treatment. 
Three patients with draining sinuses due to suppurating 
tuberculaus lymphadenitis showed prompt and striking response 
to streptomycin treatment; it is possible that recurrence of 
the in~eotion·may take place. 
Doctors and patients should be cautioned that sanatorial 
care and collapse therapy and other proven methods of treatment 
of tuberculosis should not be abandoned in favor of the 
relatively untried chemotherapeutic agen~s. Undue optimism 
on the part of the laity as to the effects of newly developed 
antibacterial agents must be avoided, sin~e morale, which is so 
important in patients with chronic debilitating diseases suoh 
. 
. as tuberculosi~, is 1an6exmined ~ premature optfumistic reports 
whioh may not be furlfilled in clinical practice. 
= 
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x. Conclusions 
It is still too early to assign the e~act place that 
streptomycin will occupy in our chemotherapeutic arsenal. 
Certainly, it holds promise of serving as a valuable addition 
1:) to our armamentarium for combatting bacterial in~ections, 
particularly those which are resistant to the action of pen-
icillin and other established agents. It has already given 
evidence of outstanding therapeutic effect in some diseases, 
such as influenzaf meningitis and tularemia; in other diseases, 
such as brucellosis and tuberculosis, results have been in~ 
' 
conclusive or disappointing. To make predictions would be 
foolhardy as well as useless, since only by continued clin-
ical investigation can the status of streptomycin in each 
disease be clarified. 
The information arising from the investigative work 
done on streptomycin is of value even apart from its specific 
clinical applications. Perhaps equally important from the 
• long range point of view is the additional light which it 
must inevitably throw upon the physico-chemical meuhanisms 
of bacteriostatic and bactericidal action both in vitTo and 
1g vivo, and upon their relations to certain properties of 
bacterial organisms. More exact appreciation of these 
fund~mental concepts, together with a better understanding of 
the ultimate nature of bodily resistance will facilitat,e 
future developments in the broad field of treatment of 
infectious disease. 
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Table II 
Antibiotics from Fungi 
Name Origin 
Penicillic acid 
Penicillium 
puberulum 
penicillin 
Citrinin 
Gliotoxin 
Fumigatin 
Claviformin·n· 
Fumigacin~~* 
Clavacin* 
Aspergillic 
Ayid 
Flavicin 
Helvolic 
Acid*-M· 
Patulin* 
Gigantic 
Acid 
Flavicidin 
Penicillium notatum 
P. chrysogenum 
Penicillium 
citrinum 
Trichoderma 
lignorum 
Aspergillus 
fumigatus 
Penicillium 
claviforme 
Aspergillus 
fumigatus 
Aspergillus 
clavatus 
Aspergillus 
flavus 
Aspergillus 
flavus 
Aspergillus 
fumigatus 
Penicillium 
patulum 
Aspergillus 
giganteus 
Aspergillus 
flavus 
Susceptible Organisms 
Gram-positive and gram-negative 
bacteria. 
Gram-positive bacteria, gono-
cocci, meningococci, spiro-
chetes, actinomyates, clostridia, 
c. diphtheriae. 
Gram-positive bacteria 
Kills gram-positive bacteria, 
s. paratyphi, s. dysenteriae, 
fungi. 
Chiefly gram-positive bacteria. 
Gram-positive and gram negative 
bacteria. 
Gram-positive bacteria. 
Gram-positive and gram-negative 
bacteria; some fungi. 
Gram-positive and gram-negative 
bacteria. 
Gram-positive bacteria. 
Gram-positive bacteria. 
Gram-positive and gram-negative 
bacteria. 
Gram-positive bacteria. 
Gram-positive bacteria. 
-lt-Claviformin, clavacin and patulin are similar if not identical. 
**Fumigacin and helvolic acid are similar if not identical. 
0 
0 
Table III 
~ntibiotics from Actinomycetes 
Name Origin 
Actinomycetin Actinomyces 
Actinomycin A A. antibioticus 
Actinomycin B A· antibioticus 
Proactinomycin :Proactinomyces 
ga.rdneri 
Streptothricin A. lavendulae 
Streptomycin A. griseus 
·susceptible organisms 
Gram-positive and gram-negative 
bacteria. 
Gram-positive bacteria and fungi. 
Gram-positive bacteria and fpngi. 
Gram-positive bacteria and gram-
negative cocci. 
Gram-positive and gram-negative 
bacteria, fungi, Mycobacteria. 
Gram-positive and gram-negative 
bacteria, Mycobacteria, Actino-
mycetes. 
0 
0 
Ta.bleJjiV 
Comparative Chemical and Biological Properties 
Of Streptothricin and Streptomycin (,,) 
Source of Antibiotic 
substance 
Medium for production 
of sustance 
Need f'or growth 
promoting substance 
Solubility 
Heat Stability 
Sensitivity to 
acids 
Effect-of Glucose 
Bacteriostatic 
Spectrum 
Activity against 
Trypanosoma 
equiperdum 
Antifungal Activity 
Toxicity to Animals 
Activity~~ 
STREPTOTHRICIN 
Actinomyces lavendulae 
Tryptone starch broth 
0 
Soluble in water, 
acid solutions, but 
not in chloroform or 
ether 
Thermostable 
Sensitive 
Inhibitory 
Certain gram-positive 
& gram-negative 
bacteria: relatively 
inactive ~gainst B. 
myooides & s. -
marcescens 
None 
Active against 
pathogenic 
·saprophytic ~ungi 
Limited to~icity; 
1.0-3 gm. of purified 
material per kg.of 
body weight 
Active 
STREPTOMYCIN 
Actinomyces 
griseus 
Nutrient 
glucose broth 
+++ 
Same 
Same 
Same 
Same 
More generalized 
action against 
bacteria 
inoludi!].g 
B.mycoides ~nd 
.§..ma.rcesoens 
None 
None 
Less toxic; 
.about ? • 0 gm. 
of purified 
material per 
kg. of body 
weight 
Active 
c 
0 
Table V 
eultural and Physiological Characteristics of the. ( ~ 
Streptomycin Producing strain of A. griseus and its Inact1ve variant. b3) 
Active Strain 
1. Antibiotic activity. Pro-
duces streptomycin in both 
shaken and stationary cult-
ures. 
~~o~u~face growth always 
heavily sporulated; grayish-
green aerial mycelium. 
3. Reaction: Medmum always 
changes to alkaline; pH 
7.5-8.5. . 
4. Glucose. Glucose com-
pletely consumed in 6-8 
days in stationary cul-
tures and in 3-4 days in 
shaken cultures. 
5. Lysis in shaken cultures. 
Shaken cultures produce veryy 
fine flocculant growth, tend-
ing to lyse slowly after 
about 15 days. 
6. Lysis in stationary cul-
tures. Surface pellicles 
stabl~; any submer~ed, 
flo·cculant growth tends to 
lyse as the surface pel-
licle develops • 
• 
7. Viscosity. Culture fil-
trate does not show any 
viscosity. 
8. Reinoculation. Inoc-
ulation of cultures with 
lysed inactive culture in-
duces no lpsis or reduc-
tion in activity. 
9. Variation. Sporulating 
strain gives rise to non-
sporulating v~riants. 
10. Sensitivity to strep-
tomycin. very resistant to 
thi_s anti biotic. 
Inactive Variant 
' 
1. No streptomycin formed either 
in shaken or. stationary cultures. 
2. No sporulating aerial mycelium; 
scant development of aerial ~yphae with 
tendency to form spores in old cultures. 
3. Reaction of medium at first acid, 
pH 5.0-6e5; later·becoming alkaline. 
4. Glucose utilized more slowly. 
' 5. Cultures produce at first 
balls of gro\'lth which change intlb 
the turbid, flocculant type; rapid 
~nd complete lysis in 7-10 days. 
6. Stationary cultures produce 
'no surface growth but flocculant, 
submerged mycelial growth which 
lyses slowly, only after a month 
or longer. 
7. Culture filtrate becomes 
viscous during or after lysis. 
8. Inoculation of cultures withh 
spores of active strain produces 
growth and antibiotic activity if 
some glucose remains. 
9. Asporogenous variants may 
reconvert to active, sporogenous 
forms. 
10. Very sensitive to this anti-
biotic. 
Table YI 
Influence of Cysteine Concent~ation upon the Activity 
of Streptomycin (s 1.) 
Mg. Cysteine per Streptomycin Activity, Units, After 
100 Micrograms of 
Streptomycin 0 hrs. 5 hrs. 24 hrs. 
o.o 37.5 37.5 25.5 
0.5 37.5 29.5 22.0 
2.5 23.0 14.0 2.0 
12.5 2.0 2.0 1 
25.0* 1.7 1.7 1 
50.0* 5.3 4.5 1.8 
·*Results obtained-with 25.0 and 50.0 mg. cysteine were 
rather confusing; several zones of alternating inhibition 
and stimulation were produced. The cysteine itself at 
similar concentrations appeared to have a marked inhibit-
ing effect on B.subtilis by the assay method. 
0 Table VII 
Concentrations of Streptomycin in Blood Serum 
Following Repeated Tinjections 
Administration of· Blood SerUm Levels 
'streptomycin (Units per oo.) 
No. Hours af'ter first dose 
Route Dose* Doses 1 3 6 9 12 
-
I.V. 100,060 3 3 1.5 3 3 1.5 
5.4 2.9 4.5 3.4 2.3 . 
I.V. 100,000 3 3 1.5 1.5 1.5 1.5 
4.6 3 4 5.4 2.8 
I.M. 100,000 3 1.5 1.5 1.5 1.5 0 
2.7 2.6 2.6 3.3 1.2 
I .M. lOO,OOO 3 1.5 ·1.5 3 - 3 1.5 
3 3.3 4.5 4.3 2.8 
I.M. 400,000 3 3 3 6 3 3 
3.6 2.1 11 3.9 . 2.3 
I.M. 400,000 3 3 3 3 3 0 
5.7 2.8 5.8 6.9 2.6 
I.V. 400,000 3 14.5 14.9 13.2 7.5 4.1 
From Heilman et al. (26) 
* given every three hours 
Method of 
Assay 
Slide cell 
Cup plate 
·Slide cell 
- Cup plate 
Slide cell 
Cup plate 
Slide cell 
Cup plate 
Slide cell 
Cup plate 
Slide cell 
Cup plate 
Cup plate 
0 ' Table VIII 
) Concentrations ;of Streptomycin in Blood Serum Following Single or Intermittent Injections 
-
-
Blood Serum Levels 
(Units per cc.) 
Amount Hours After Injection ( 
Route of per dese 
.1. 
Metho_d of 
Admin. ~units} 2 1 - 2 3 4 As sax 
I.v. 100,000 6 6 3 0 • • Slide cell 
I.M. 100,000 3 3 3 3 • • Slide cell 
Subcut. 100,000 3 3 3 1.5 • • Slide cell 
Subcut. . ~200,000 6 6 6 6 • • Slide cell 8.8 8.8 7.2 6.2 • • Cup plate 
} 200,000 12.5 6 6 3 Slide cell Subcut,- • • 
10 7.7 6 •• • • Cup plate 
Subcut. 200,000 12.5 25 6 6 • • Slide cell 
~ 
Subcut.* 100,000 • • 12.5 • • • • •• Slide cell 
Subcut.* 100,000 •• 12.5 25 6 • • Slide cell 
Subcut.* 115,000 • • 12.5 • • • • •• Slide cell 
Subcut.* 115,000 • • 6 • • •• • • Slide cell 
Subcut.* 150,000 • • 12.5 • • •• • • Slide cell 
' 16;'6 Cup plate • • • • •• • • 
Subcut.* 250,000 • • 25 25 25 25 Slide cell 
31 24 16 10 Sup plate 
. 
, From -Heilman et al. ( 26) 
*Intermittent injection every three hours. 
0 
Table :ot 
Bactericidal Action of Streptomycin Upon Pr. vulgaris 
·streptomycin1 units Pr. vulgaris Pr. vulgaris Pr. vulgaris per ml. W 1 W 2 R 
At start 
--------------- -----------------
''I ,.. 
"59:5 45.5 
After 28 hours·' 
0 375.-0 615.0 
1 o.ol 0.65 
5 o .. ~~f- O*~~j~HH} 
25 0 0~~*, ~~{t-* 
-l~ No. of cells in millions per ml. 
** One colony on a plate from 1:1000 dilution 
-ll--1-.... A-7-8 colonies on a plate from 1;10 dilution 
26.0 
:lncubation 
5"60.0 
190.0 
9.0 
3.1~ 
• 
0 
~ 
) 
Table X 
Range in Sensivity of Different Bacteria and Actinomycetes 
to the Bacteriostatic Action of Streptomycin~~ {82) 
Organism 
Aerobacter aerogenes 
Bacillus anthracis 
B. cereus 
B. megatherium 
B. mesentericus 
B. mycoides 
B. subtilis 
Brucella abortus 
Br. melitensis 
Br. suis 
Clostridium butylicum 
Cl. septicum 
Cl. sordellii 
Cl. tetani 
Cl. welchii 
Corynebacterium diphtheriae 
Diplococcus pneumoniae 
Eberthella typhi 
Erysipelothrix muriseptica 
Escnerichia coli 
E. communior 
Hemophilus influenzae 
H. pertussis 
Listerella monocytogenes 
Klebsiella ozenae 
X. pneumonfae 
M~lleomyces mallei 
~iycobacterium avium 
M. phlei 
M. tuberculosis, var. hominis 
Neisseria gonorrohoeae 
N. intracellularis 
Pasteurella aviseptica 
P. lepiseptica 
P. pestis 
P. tularensis 
Phytomonas pruni 
Proteus vulgaris 
Pseudomonas aeruginosa-lH:· 
Ps. fluorescens** 
Sarcina lutea 
Serratia marcescens 
Salmonella aertrycke 
S. enteritidis 
S. sc~ottmfilleri 
Salmonella sp. 
Shigella paradysenteriae 
Staphylococcus aureus*~* 
Micrograms 
0.5-2.5 
0.375 
0.83 
0.25-3.0 
1.67 
0.1-3.8 
0.12-1.0 
0.5-3.75 
0.5 
0.5 
8.34 
>105 
>105 
>104 
.>.104 
0.375-3.75 
8.0 
l .. D-37.5 
2.5 ' 
0.3~;.i:;'t5~ 
l.0-4.0 
.~.l~5q~s.o 
1.25-3.0 
2.5 
0.375-1.5 
0.625-8.0 
10->10.0 
10.0 
0.12 
0.15 
5.0 
5.0 
15.00 
0.5-2.5 
0.75-1.5 
0.1-5-0.3 
0.25 
0.4-3.0 
2.5-25.0 
12.5 
0.25 
1.0 
4.0-10.0 
0.5 
2.0 
60.0 
0.25-3.75 
0.5->16.0 
0 Organism 
Streptococcus faecalis 
s. hemolyticus 
s. lactis 
S. salivarius 
S. viridans 
Vibrio comma 
Actinomyces bovis 
Nocardia asteroidea 
N. gypaoides 
Streptomyces albus 
s. antibioticus 
s. lavendulae 
Streptomyces sp. 3462 
Table X (continued) 
Micrograms 
50.0 
2.0-)16.0 
4.0 
5.0-25.0 
>16 
6.0-37.5 
3.75 
12.5 
4.0-12.5 
0.4-1.25 
(0 .4 
1.25 
4-l2.5 
*Micrograms of streptomyuin per ml. of suitable medium 
required to inhibit growth. 
~Hi- Out of a group of Ps. aeruginosa and Ps. fluorescens 
(by Hirshfeld) some required over 256 micrograms per ml. 
to inhibit growth. · 
*** Some staphylococci have been repotted (by Hirshfeld) 
to require over 256 micrograms per ml. to inhibit growth. 
Table XI 
Bacteriemia Owing to Gram-negative Organisms (32) 
0 Infecting Associated Days Total Route • Result Organism Lesion Treated Do Se-lf. of Adm. 
8 Escherichia pyelonephritis 7 1,400,000 I.v. Good. Recovery coli and uremia drip from bacteriemia 
but death from 
coronary occlusion 
A. Severe urinary Good. Recovery 
aerogenes tract infection 14 19,000,000 I.V. from bacteriemia (2 courses) d;!'iP but assoc. E. coli 
bacillu:bia 
remained 
Ps. Prostatic ob-
aeruginosa struction.with 7 14,000,000 I.v. Good. recovery 
severe cystitis drip fr,om bacteriemia 
and pyelonephritis but E. coli ba-
cilluria remained 
E. 
coli Pyelonephritis 13 20,000,000 r.v. Good. Recovery 
and ,9.iabetes drip from bacteriemia 
and but E. coli. ba-
I.M. cilluria remained 
Salmonella, Severe urinary 17 20,400,000 I .M. Good. Recovery 
Proteus tract infection from bacteriemia 
ammoniae but Proteus in-
faction in urine 
remained. 
Brucella Undulant fever 14 14,600,000 I .V .r Doubtful. Blood 
with possible drip cultures became 
endocarditis and neg. but further 
I.M. observation · 
necessary 
Brucella Undulant fever 36 43,000,000 I .V. Good. Ultimate (3 courses) drip recovery. See 
text p. 58. 
Brucella Undulant fever 7 7,000,000 I .M. Doubtful. Blood 
and cultures became 
I. V. negative under 
drip treatment but 
symptoms· per ... 
sis ted 
a * S units 
~·1 
:1 
0 
I 
Inf-ecting 
organism 
Ps. aeruginosa 
E. coli 
Ps • aeruginosa 
Ps. aeruginosa 
Ps. aeruginosa 
E. coli 
Ps. aert:tginos~ 
Pr. ammoniae 
E. coli 
A. aerogenes 
Pr. ammoniae 
Ps. aeruginosa 
s. taecalis 
s. aureus 
Ps. aeruginosa 
Ps. aeruginosa 
Proteus 
ammoniae 
A. aerogenes 
E. coli 
A. aerogenes 
i£- s units 
Table XII 
Infections of the Urinary Tract (32) 
Days Total 
Treated Dose* 
Route 
of Adm. 
17 16,600,000 I.M. 
8 
4 
7 
13 
5 
5 
9 
6 
4 
7 
6 
8 
(3 courses) 
7,200,000 
4,000,000 
5,600,000 
14,400,000 
4,000,000 
6,000,000 
9,000,000 
6,000,000 
4,000,000 
I,M. 
I .M. 
I.M. 
I.M. 
I.M. 
I .M. 
I.M. 
I .M. 
I .M. 
7,000,000 I.M. 
4,800,000 I.M. 
6,400,000 I .M. 
Result 
Good. Definite improvement 
following streptomycin com-
bined with surgical treat-
ment. 
Good.Urine cultures be-
came negative and temp-
erature returned to normal. 
Failure. 
Good. Urine cultures 
becaJlle negative. 
Good. Recovery complete. 
Good. Sterile urine at 
time of dismissal. 
Good. Sterile ct:tltures 
after third day of treatment. 
Good. Urine cultures neg-
atiVe after 8 days of treat-
ment. 
Good. Penicillin and sulfa-
thiazole ineffective. Sterile 
urine following streptomycin. 
Doubtful. Epididymitis sub-
sided and temperature be-
came normal; but cultures 
~ remained positive ~" 
Good. Ct:tltures became nega-
tive; but much additional 
treatment was given. 
Failure. Temporary improve-
ment followed by recurrence 
of E. coli bacilluria. 
Good. A. aerogenes infection 
controlled; Strep. faecalis 
infection developed while 
under treatment. 
0 
Table XIII 
Treatment of Miscellaneous Infections With 
streptomycin (32) 
Diagnosis 
.osteomyelitis 
Ruptured 
bladder with 
cellulitis 
Cholangitis 
Meningitis 
Meningitis 
].1eningi tis 
Meningitis 
Ozena 
Infecting 
Organism 
Days Total Dose 
Treated {units) 
Ps. 
aeruginosa 3 3,000,000 
None 
identif'led 9 5,850,000 
E. coli 10 8,000,000 
H. ibnfluenzae 8,400,000 
type B 10 
H. influenzas 5,800,000 
type B 7 
H. influenzae 
type B. 12 10,100,000 
Adm. Result 
Failure. Suppiy 
of streptomycin 
Local exhausted. 
and I.V. 
drip 
Failure. surgical 
I.M. drainage nedess-
ary. · 
I.M. Good. Remained 
afebrile after 
treatment began. 
Bile sterile. 
I.M. and Good. Patient re-
intra- ceived serum and 
thecally sulfonamides in 
addition to strep-
tomycin. 
t 
I.M. and Gnod. Sulfadia§ine 
intra- ana-sulfamerazine 
theca~ in addition to 
IM and 
intra-
thecal 
streptomycin. 
Good. No other 
treatment except 
streptomycin. 
H. 18 
influenz~e 
18,500,000 IM and 
intra-
thecal 
Good. Infection 
controlLed but deed 
2 months later of 
post-meningitis 
hydrocephalus (com-
municating) • 
K. 10"" 10,000,000 
pneumoniae 
IM and 
IV drip 
Doubtful. Culture 
became negative. 
Symptomatic. im-
provement. 
(Continued) 
0 
<! 
0 
o, 
Diagnosis 
Ozena 
Ozena 
Ozena 
a 
Infecting 
Organism 
K. 
pneumoniae 
K. 
pneumoniae 
K. 
pneumoniae 
Table XIII (continued) 
Days Total nose 
Treated {units} 
14 14,000,000 
12 9,600,000 
10 10,000,000 
Adlil. Ref;lult 
I .M. Failure. Temporary 
improvement but 
organism became 
resistant •. 
I.M. Doubtful. Symptom-
atic improvement. 
Obtained negative 
culture. 
I .. M. Doubtful. Culture 
became negative and 
aymptomatic im-
provement but no 
follow-up avail-
able 
0 
Table XIV 
Streptomycin in Pulmonary Suppurative Disease (32) 
Infecting 
Organism 
Days Total dose 
Treated (units) 
K. 
pneumoniae 7 1,120,000 
K. 
pneumoniae 10 2,000,000 
Paracolon 
bacillus 30 30,000,000 
Ps.aeruginosa 
E. CQli 4-i 4,500,000 
E-. coli 
H. infll1enzae 
8 1,900,000 
Admini s tra ti·on Results 
I.M. and Good. Klebsiella elim-
nebulization inated from sputum 
after treatment. Re-
sidual bronchiectasis. 
' 
I.M. adq Good. Sputum has remain~ 
nebulization negative for 11 months. 
Intramuscular Good. Sputum became 
negative. Bronchiectasis 
and fibrosis persisted/ 
Nebulization 
Nebulization (1 day) and 
supraglottical 
Good. Sputum became 
negative. 
Failure. Treatment dis-
continued. Increasing 
dyspnea with decom-
pensated emphysema. 
0 
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